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ABSTRACT 
 
Major Depressive Disorder (MDD) is a persistent, severe mental disorder with 
approximately 16% lifetime prevalence. Anhedonia has long been recognized as 
a core feature of the disorder. Described as a reduction in the interest or 
enjoyment derived from pleasurable activities, clinical assessment of anhedonia 
has primarily relied on clinician-rated or self-reported hedonic responses to past 
experiences or laboratory stimuli, despite the well-established clinical observation 
that anhedonia is often accompanied by reductions in motivation. The lack of 
attention to possible motivational deficits in anhedonia has hindered efforts to 
uncover the pathophysiology of this debilitating symptom, as substantial 
preclinical evidence suggests that motivational and consummatory aspects of 
reward processing possess distinct neurobiological substrates. In particular, the 
mesocorticolimbic dopamine (DA) system has long been hypothesized to play a 
role in the pathophysiology of anhedonic symptoms, but empirical validation of 
this hypothesis has remained elusive. In this dissertation, I suggest that the lack 
of a clear demonstration of DA dysfunction in anhedonic depression may result 
from the reliance on measures of anhedonia that primarily emphasize the 
subjective experience of pleasure, while preclinical data strongly implicate DA in 
primarily motivational aspects of reward processing. To address this issue, I 
introduce a novel behavioral measure that may be used to address motivational 
deficits in patient populations experiencing anhedonia. Dubbed the Effort 
Expenditure for Rewards Task (EEfRT or “effort”), this measure was adapted 
viii 
from preclinical effort-based decision-making paradigms that have been 
successfully used to demonstrate the role of DA function in determining an 
organism’s willingness to expend physical effort in pursuit of a given reward. 
Over three empirical studies, I demonstrate that the EEfRT is sensitive to 
individual differences in reward motivation, which are in turn linked to anhedonic 
traits, human DA function and clinical depression. The results of these studies 
offer novel insights into the neurobiological mechanisms underlying motivational 
aspects of anhedonic symptoms, with important implications for future treatment 
and prevention.  
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1 
Introduction 
 With a lifetime prevalence of approximately 16% (Kessler, et al., 2003), 
Major Depressive Disorder (MDD) is predicted to become the second leading 
cause of death and disability in the United States by the year 2020 (Murray & 
Lopez, 1997).  Dating back to the original Feighner criteria published in 1972, 
anhedonia has long been presumed as a core feature of MDD (Feighner, 1972).  
The DSM-IV-TR (American Psychiatric Association, 1994) defines anhedonia as 
diminished interest or pleasure in response to stimuli that were previously 
perceived as rewarding during a pre-morbid state (DSM-IV-TR). Along with 
depressed mood, anhedonia is one of two required symptoms for a diagnosis of 
MDD (APA, 1994). Recent reports estimate that approximately 37% of individuals 
diagnosed with MDD experience clinically significant anhedonia (Pelizza & 
Ferrari, 2009). Moreover, prior studies indicate that anhedonia predicts 
depressive symptoms (Hundt, Nelson-Gray, Kimbrel, Mitchell, & Kwapil, 2007) 
time to recovery (McFarland, Shankman, Tenke, Bruder, & Klein, 2006), and 
poor treatment outcomes (Kasch, Rottenberg, Arnow, & Gotlib, 2002; McFarland, 
et al., 2006 ; Spijker, Bijl, de Graaf, & Nolen, 2001). Anhedonia is also a 
particularly difficult symptom to treat as accruing evidence suggests that current 
first-line pharmacotherapies (e.g., SSRIs) do not adequately address 
motivational and reward-processing deficits in depression (APA, 2000; Dunlop & 
Nemeroff, 2007; McCabe, Cowen, & Harmer, 2009; Nutt, et al., 2007; Price, 
Cole, & Goodwin, 2009; Shelton & Tomarken, 2001). 
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The Challenge of Heterogeneity in Major Depressive Disorder 
 For several decades now, popular culture has likened the psychiatric 
diagnostic construct of Major Depressive Disorder (MDD or “depression”) as 
being akin to medical diagnosis of fever; both possess several clearly identifiable, 
surface-level features that belie a myriad possible culprits. Like fever, the causes 
of MDD are too varied and individual that the diagnosis offers little informational 
value in terms of guiding treatment and prevention. In an effort address this 
problem, a longstanding goal of the National Institute of Mental Health has been 
to identify their biological basis. Since the earliest biological accounts of 
depressive symptomatology (Schildkraut, 1965), researchers have consistently 
identified disturbances in a wide range of biological systems when comparing 
MDD patients with healthy controls, including multiple classes of 
neurotransmitters (monoamines, GABA, glutamate) (Gabbay, et al., 2012; 
Owens & Nemeroff, 1994; Pittenger, Sanacora, & Krystal, 2007; Sanacora, et al., 
2004; Walter, et al., 2009), endocrine systems (Holsboer, 2000), immune 
systems (Miller, Maletic, & Raison, 2009), neurotrophin systems (Duman & 
Monteggia, 2006), region-specific functional and structural alterations and 
patterns of functional connectivity (Keedwell, Andrew, Williams, Brammer, & 
Phillips, 2005a; Pizzagalli, et al., 2009; Sheline, Price, Yan, & Mintun, 2010). 
These effects have proven to be stable and robust, as determined by multiple 
meta-analyses (Fitzgerald, Laird, Maller, & Daskalakis, 2008; Koolschijn, van 
Haren, Lensvelt-Mulders, Hulshoff Pol, & Kahn, 2009). Despite this wealth of 
positive findings, however, none of these biological systems appear to show 
3 
strong enough specificity for the disorder. That is to say, while mean differences 
between depressed and non-depressed samples emerge consistently, it is 
invariably a subset of patients in each study that account for the overall group 
difference (Raison & Miller, 2011). Consequently, we have yet to uncover a 
single biological process that can accurately be described as being necessary for 
the MDD symptomatology. 
 Two basic conclusions can be drawn from this substantial body of work. 
The first is that MDD is unquestionably a biological disorder, this is true despite 
persistent notions that depression is “caused” by intuitively appealing factors, 
such as recent losses and stressors (Kendler, 2012; Kendler, Myers, & 
Halberstadt, 2011). The second is that the biological basses of depression may 
be so heterogeneous that the MDD construct is of little use for the purposes of 
studying underlying biological mechanisms (Hyman, 2002, 2010). This is true not 
only in regards to the presence or absence of specific symptoms within a 
disorder (diagnostic heterogeneity), but also for the presence or absence of co-
morbid conditions (heterogeneity of co-morbidity), etiological pathways involved 
in disorders (etiological heterogeneity).  
 Attention to these multiple forms of heterogeneity has proven critical for 
elucidating the neurobiological pathways involved. For example, under the DSM-
IV definition of a Major Depressive Episode, there are 126 unique combinations 
of symptoms possible, with two MDD positive individuals sharing only a single 
symptom of the disorder.  Such heterogeneity in how an individual meets criteria 
may be both practical and theoretically appropriate, but it may also mask 
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important associations that are related to specific symptoms, rather than the 
whole diagnostic category.  Similarly, co-morbidity may obscure disorder-specific, 
or symptom-specific associations. For instance, while multiple studies have 
shown that individuals with depression exhibit increased amygdala activation in 
response to negatively-valenced stimuli (Fu, et al., 2004; Siegle, Carter, & Thase, 
2006; Siegle, Steinhauer, Thase, Stenger, & Carter, 2002; Siegle, Thompson, 
Carter, Steinhauer, & Thase, 2007), newer evidence suggests that this amygdala 
activity may occur primarily in individuals with MDD and co-morbid anxiety 
symptoms (Beesdo, et al., 2009).  Heterogeneity in etiological factors may also 
be important. In testing the role of the Hypothalamic-Pituitary-Adrenal (HPA) Axis 
in MDD, it has been demonstrated that individuals with depression and early life-
trauma exhibit structural reductions in regions involved in HPA axis regulation, 
while individuals with depression but not early-life trauma do not (Treadway, 
Grant, et al., 2009; Vythilingam, et al., 2002). In sum, the use of case-control 
designs to uncover the pathophysiological mechanisms underlying the symptoms 
of MDD that ignore this type of etiological heterogeneity may conceal important 
neurobiological differences (Heim, Plotsky, & Nemeroff, 2004). 
 
Confronting Heterogeneity: Anhedonia Fever 
 One solution to this problem has been to focus on identifying the biological 
basis of specific symptoms within MDD, with the hypothesis that individual 
symptoms would show less heterogeneity than the disorder as a whole (Hasler, 
Drevets, Manji, & Charney, 2004). Reward-related symptoms represent an 
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excellent opportunity for this type of translational neuroscience approach, given 
the vast basic science literature from which to draw upon (Berridge & Robinson, 
2003; Gold et al., 2008). However, application of this important preclinical work to 
human conditions is hampered by the enormous heterogeneity in symptom 
presentation. As with the diagnostic category of MDD as a whole, individual 
symptoms exhibit significant variability in their specific nature, which are often 
difficult to assess using standard self-report and clinician-rated assessments. 
While less commonly acknowledged than the above-mentioned forms of 
heterogeneity, symptom heterogeneity represents an additional barrier to the 
identification of biological substrates that can lead to causal explanations.  
 In the case of anhedonia, the DSM-IV-TR states that individuals meeting 
criteria “may report feeling less interest in hobbies, ‘not caring anymore,’ or not 
feeling any enjoyment in activities that were previously considered pleasurable” 
(American Psychiatric Association, 1994, p. 349). In other words, clinical 
diagnosis of anhedonia does not discriminate between a decrease in motivation 
and a reduction in experienced pleasure. The failure to draw such a distinction 
may reflect the long-held assumption that people are motivated to pursue the 
things they find pleasurable, and vice-versa. More critically, it suggests that the 
analogy of fever may be applicable even at the symptom-level, where anhedonia 
emerges as a syndrome within itself with multiple etiologies and 
pathophysiological mechanisms.  
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Symptom-level Heterogeneity and the Neurobiology of Anhedonia 
 In this dissertation, I argue that heterogeneity at the level of symptom 
definition is at least as problematic as the more commonly acknowledged issues 
of co-morbidity or etiological variability in MDD as a whole. In making this 
argument, I suggest that the distinction between the motivational and hedonic 
aspects of anhedonia is critical, especially when attempting to elucidate 
neurobiological pathways underlying the expression of this symptom. Indeed, 
overly broad definitions may sometimes point towards spurious relationships 
between symptom and substrate. For example, early models of anhedonia 
posited a central role for the monoamine neurotransmitter dopamine (DA) 
(Willner, 1983a, 1983b, 1983c), given preclinical evidence suggesting that DA 
mediated an organism’s experience of pleasure in response to rewarding stimuli 
(Wise, 1980). In the intervening quarter-century however, only half of this original 
hypothesis has found empirical support. Namely (and as described in Chapter 
III), subsequent research using neuroimaging, pharmacological and genetic 
methods in both humans and animals has provided some support for the claim 
that DA function is impaired in at least a sub-population of individuals with MDD 
(Dunlop & Nemeroff, 2007; Yadid & Friedman, 2008). However, contrary to the 
original anhedonia hypothesis, the conceptualization of DA as being primarily 
related to pleasure has been largely abandoned (Berridge & Robinson, 2003; 
Salamone, Correa, Farrar, & Mingote, 2007). 
 These two developments raise a potential problem: if alterations in DA are 
a significant component in the pathogenesis of MDD but are unrelated to deficits 
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in experience of pleasure, what is their functional and clinical consequence? 
While it is often assumed that these processes are tightly coupled at both the 
biological and phenomenological level, preclinical data on the biological bases of 
reward processing has largely challenged this view. Indeed, expanding off the 
work of Berridge and others, one could plausibly sub-divide the anhedonia 
construct in terms of deficits in the hedonic response to rewards (“consummatory 
anhedonia”) and a diminished motivation to pursue them (“motivational 
anhedonia”), which can be seen as roughly corresponding to the reward-
processing components of ‘liking’ and ‘wanting” proposed in the preclinical 
literature (Berridge & Robinson, 1998, 2003). These distinctions have been 
largely overlooked in the extant empirical literature on MDD, which may explain 
why this literature is replete with inconsistent findings (Forbes, 2009).  
 This strategy is not entirely new, and indeed echoes decades-old 
theoretical models and clinical observations. Neurobiological models of 
personality have previously emphasized dissociations between “approach” and 
“consumption” of rewards, with the former constituting a behavioral activation 
system.  These models further posited that DA is primarily linked with approach 
emotions, and might therefore underlie individual differences in reward seeking 
behaviors and psychopathology (Cloninger, 1987; Depue & Collins, 1999; Depue 
& Iacono, 1989; Gray, 1987). Similarly, this dissociation has been noted in the 
clinical literature; the psychiatrist Donald Klein noted that many patients with 
depression and anhedonia appeared to enjoy rewards that were readily 
available, yet complained bitterly about feeling no desire to obtain them (Klein, 
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1987). However, there has yet to be rigorous, objective approach to the 
exploration of motivational deficits in MDD, and their neurobiological 
underpinnings.  
 The goal of this dissertation is to provide such an approach. To 
accomplish this objective, the studies described herein have focused on the 
development and validation of a translational experimental paradigm that can be 
used to objectively assess reward motivation in humans. Using this measure, 
these studies proceed to explore the personality and neurochemical correlates of 
individual differences in reward motivation, and their relevance to MDD.  
  
Specific Aims 
 Specific Aim 1: Design and validate a translation measure of effort-based 
decision-making for use in humans 
 The goal of this aim was to design a behavioral measure that would be 
sensitive to individual differences in effort-based decision-making in humans, and 
that would parallel tasks used in the animal literature closely enough to facilitate 
translational approaches to testing hypothesis of neurobiological mechanisms. 
Chapters II and III of this dissertation provide a review of clinical and preclinical 
studies that informed the rationale and design considerations for this measure, 
and Chapter IV presents data from a pilot study focused on providing initial 
validation of the finalized task design.  
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Specific Aim 2: Explore the role of DAergic circuitry in human effort-based 
decision-making 
 One of the primary motivating factors for the translation of an effort-based 
decision-making paradigm from animals to humans has been to specifically 
explore the role of DA as neurochemical substrate of motivation. Chapter V of 
this dissertation describes a study relating individual differences in effort-based 
decision-making in humans to variability in mesocorticolimbic DA function. DA 
function was assessed in this study using PET imaging of D2/D3 receptor 
availability both on and off a d-amphetamine challenge paradigm.   
 
Specific Aim 3: Examine the presence of effort-based decision-making deficits in 
MDD 
 Having developed an experimental paradigm that is successfully modeled 
after effort-based decision-making studies in animals (Aim 1), and demonstrating 
its ability to translate preclinical models of DA function (Aim 2), the goal of Aim 3 
was to explore behavioral performance on this measure in a clinical sample. As 
described in Chapter VI, a sample of MDD patients and matched healthy controls 
were compared to test the hypothesis that MDD patients (or at least a subset of 
them) would exhibit less willingness to work for rewards.  
10 
CHAPTER II 
ASSESSMENT OF ANHEDONIA IN MDD 
 
  As outlined in the introduction, the guiding hypothesis of this dissertation 
is that anhedonia is a complex symptom with multiple manifestations, etiologies, 
and pathophysiological mechanisms, all of which carry significant implications for 
treatment and prevention. To address this problem, I have recommended the 
division of anhedonia into motivational and consummatory sub-components. In 
this chapter, I provide a review of clinical studies of anhedonia in MDD that 
provide the basis for this proposal.   
  
Diagnosis of Anhedonia in MDD 
 According to the current DSM-IV, anhedonia is one of two symptoms 
required for a diagnosis of MDD, the other being dysphoric mood (APA, 1994), 
suggesting that anhedonia is a “core feature” of the disorder. This requirement 
would imply that as compared to the other 8 symptoms of MDD, the presence or 
absence of anhedonia should have greater sensitivity and specificity for an MDD 
diagnosis than other symptoms, such as appetite disruption.  However, the 
psychometric properties of symptoms in MDD have only recently been subjected 
to rigorous empirical analysis. Beginning in 2006, the Rhode Island Methods to 
Improve Diagnostic Assessment and Services (MIDAS) project published a 
series of papers exploring the psychometric aspects of DSM criteria as assessed 
using a structured interview in a sample of 1523 subjects (Zimmerman, 
11 
McGlinchey, Young, & Chelminski, 2006). As part of this study, they also made 
head-to-head comparisons between current DSM-IV symptom criteria and 
theoretical criteria, such as helplessness/hopelessness, lack of emotional 
reactivity, and diminished drive (a construct similar to motivational anhedonia). 
This additional diminished drive criterion is distinct from the typical Structural 
Clinical Interview for DSM Axis-I Disorders (SCID) assessment of anhedonia, 
which does not dissociate between motivational or consummatory aspects of 
reward; in keeping with DSM-IV criteria, the SCID simply asks patients whether 
they “have lost interest or pleasure in things that they usually enjoy”. Strikingly, 
diminished drive in combination with reported loss of energy criterion had the 
second highest odds-ratio for predicting a diagnosis of depression (50.1), ranking 
only below sad mood (61.2) and significantly greater than anhedonia as 
assessed by the SCID (29.7) (McGlinchey, Zimmerman, Young, & Chelminski, 
2006). This finding is all the more impressive when considering the fact that the 
criterion of diminished drive is handicapped in comparison to the DSM anhedonia 
criteria, as only the latter bears directly on diagnostic outcome. While these 
results support the designation of anhedonia as reflecting a core feature of MDD, 
it also highlights the importance of motivation and drive, as compared to the 
standard assessment item that does not discriminate between motivational and 
consummatory aspects of this symptom.  
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Dimensional Assessment: Self-Report Measures 
 Dimensional assessment of anhedonic symptom severity has primarily 
been achieved through self-report instruments. A content review of items used in 
the most common anhedonia measures reveals that they unanimously 
emphasize the experience of pleasure in response to positive stimuli, with little or 
no attention to diminished drive or motivation.  This includes the Chapman 
Anhedonia Scale (Chapman, Chapman, & Raulin, 1976), the Scale of Negative 
Symptoms (SANS; (Andreasen, 1982), the Fawcett-Clark Pleasure Scale, 
(FCPS; (Fawcett, Clark, Scheftner, & Hedeker, 1983) and the Snaith-Hamilton 
Pleasure Scale (SHAPS; (Snaith, et al., 1995). It is also worth noting that several 
of these scales were developed with a primary focus on schizophrenia 
(Chapman, SANS) rather than depression. Symptom severity instruments 
specific to depression often assess anhedonia with a small number of items; a 
single question in the case of the 17-item Hamilton Depression Rating Scale 
(Hamilton, 1960), two items on the 21-item Beck Depression Inventory (BDI 
anhedonia scale; (Beck, Steer, Ball, & Ranieri, 1996)) and four on the 30-item 
Inventory of Depressive Symptoms. Importantly, none of these scales have made 
an explicit attempt to dissociate between pleasure and motivational aspects of 
anhedonia. More recently, the Temporal Experience of Pleasure Scale (TEPS; 
(Gard, 2006) was developed to assess anticipatory and consummatory pleasure. 
This scale is a promising advance, though it is unclear whether the experience of 
pleasure when anticipating rewards is an identical construct to reward motivation, 
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and its application in MDD patient populations will be necessary to determine its 
utility for parsing clinical anhedonia. 
 In seeking to assess the relevance of these commonly used anhedonia 
assessment inventories, one recent study used a 10-indicator, 3-factor 
confirmatory factor analysis model to assess multiple measures of depression 
and anhedonia in a sample of controls and individuals with MDD. Anhedonia 
questionnaires included the Chapman, FCPS, and SHAPS, as well as clinical 
symptom inventories (BDI and Beck Anxiety Inventory; BAI). Using this 
approach, they identified three latent variables reflecting hedonic capacity, 
depressive symptoms and anxiety symptoms, and found that the hedonic 
capacity and depression variables were only moderately associated (factor 
loading = -0.20) (Leventhal, Chasson, Tapia, Miller, & Pettit, 2006).  
 Finally, the Mood-Anxiety Symptoms Questionnaire (MASQ) developed by 
Watson and Clark (Watson, Clark, et al., 1995; Watson, Weber, et al., 1995), 
includes a number of items related to lowered positive affect and interest, some 
of which appear related to aspects of anhedonia. However, these items are 
generally not treated separately from the larger scales that contain them, which 
remain relatively heterogeneous. Therefore, collapsing across these different 
forms of reward deficits may obfuscate the results, and may contribute to 
weaknesses in fitting a three-factor model across samples (Buckby, Cotton, 
Cosgrave, Killackey, & Yung, 2008; Burns & Eidelson, 1998; Kiernan, Laurent, 
Joiner, Catanzaro, & MacLachlan, 2001).  
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Dimensional Assessment: Laboratory Measures 
 In laboratory settings, a number of studies have examined affective 
responses to positively-valenced stimuli as a means of exploring the nature of 
anhedonic symptoms. These studies have suggested that individuals with 
depression generally rate positively-valenced stimuli as being less positive, less 
arousing, or less able to affect their mood as compared to controls (H. 
Berenbaum, 1992; H. Berenbaum, Oltmanns, T.F., 1992; Dunn, Dalgleish, 
Lawrence, Cusack, & Ogilvie, 2004; Rottenberg, Gross, & Gotlib, 2005; 
Rottenberg, Kasch, Gross, & Gotlib, 2002; Sigmon & Nelson-Gray, 1992; Sloan, 
Strauss, Quirk, & Sajatovic, 1997; Sloan, Strauss, & Wisner, 2001; Wexler, 
Levenson, Warrenburg, & Price, 1994) although a larger number of studies have 
reported no group differences in these ratings (Allen, Trinder, & Brennan, 1999; 
Dichter, Tomarken, Shelton, & Sutton, 2004; Forbes & Dahl, 2005; Gehricke & 
Shapiro, 2000; Kaviani, et al., 2004; Keedwell, et al., 2005a; Keedwell, Andrew, 
Williams, Brammer, & Phillips, 2005b; Mitterschiffthaler, et al., 2003; Renneberg, 
Heyn, Gebhard, & Bachmann, 2005; Surguladze, et al., 2005; Tremeau, et al., 
2005; Tsai, Pole, Levenson, & Munoz, 2003).  
 A potential caveat to this approach is whether reductions in affective 
responsiveness to positively-valenced stimuli are specific to experienced 
pleasure. One alternative explanation is that individuals with depression simply 
show a global flattening that encompasses both positive and negative emotions. 
Supporting the affective-flattening hypothesis, a recent meta-analysis of studies 
that measured physiologic or subjective affective responses found that 
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depression was associated with blunted reactivity to both positively- and 
negatively-valenced stimuli (Bylsma, Morris, & Rottenberg, 2008). Although it is 
notable that in the Bylsma analysis the effect size for positive stimuli is roughly 
double that for negative stimuli, their results suggest that at least part of the 
decline in hedonic responses may be due to a generalized affective blunting, 
rather than a specific deficit in experienced pleasure.  
 The “sweet taste test” provides another approach to assessing hedonic 
capacity.  As part of the sweet taste test, participants rate the pleasantness of 
different sucrose concentrations. An advantage of this test is that it closely 
mirrors animal measures of hedonic experience.  It is therefore of particular 
interest hat across four separate studies using the sweet taste test, individuals 
with depression and matched controls have shown no differences in reported 
hedonic impact (Amsterdam, Settle, Doty, Abelman, & Winokur, 1987; Berlin, 
1998; Dichter, Smoski, Kampov-Polevoy, Gallop, & Garbutt; Kazes, et al., 1994). 
On the surface this suggests that there is no deficit in hedonic capacity to 
experience a natural reinforcer in MDD.  A concern may be raised, however, as 
there are substantial individual differences in taste sensitivity (Duffy & Bartoshuk, 
2000) that may make such measures insensitive to state changes in hedonic 
perceptions.  In summary, the literature suggests reductions in hedonic capacity 
in MDD, although the generalizability of such deficits remains unclear.  
 Additional laboratory studies have used reinforcement paradigms to 
explore anhedonia in depression. One well-replicated finding has been that 
individuals with depression fail to develop a response bias towards rewarded 
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stimuli (Henriques, Glowacki, & Davidson, 1994; Pizzagalli, Iosifescu, Hallett, 
Ratner, & Fava, 2008; Pizzagalli, Jahn, & O'Shea, 2005). These paradigms use 
discrimination tasks in which subjects must categorize a briefly presented 
stimulus as belonging to category A or B. Importantly, these paradigms use a 
pay-off matrix so that subjects are more rewarded for correctly guessing category 
A, as opposed to category B, with no punishment associated with incorrect 
guesses. Healthy control subjects typically develop a response bias toward the 
more rewarding option, whereas MDD patients do not. These elegant studies 
provide strong evidence for an insensitivity to reward-relevant information in 
MDD. One limitation, however, is whether these reinforcement deficits are driven 
by reduced hedonic capacity, diminished motivation, or both. 
 Finally, several recent studies compared ratings of experienced emotion in 
individuals with current depression, remitted depression and never depressed 
controls across conditions that involved anticipating and experiencing rewards 
and punishments (McFarland & Klein, 2009). Participants rated their emotions 
across ten dimensions in response to four experimental conditions: anticipating 
monetary rewards, anticipating an unpleasant sensory stimulus (cold press), no 
change, and avoiding an unpleasant sensory stimulus. No differences between 
the three groups were reported for anticipating unpleasant stimuli, no change, or 
the avoidance of an unpleasant stimulus. In contrast, during reward anticipation, 
individuals with current MDD showed significantly reduced ratings of positive 
emotions as compared to controls, and slightly reduced ratings compared to 
individuals with prior depression. Although this study did not test motivation per 
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se, these data provide novel evidence of a deficit in experienced emotion during 
reward anticipation in MDD.  
 
Reconciling Laboratory and Self-Report Measures of Anhedonia 
 In comparing clinical, self-report and laboratory measures of anhedonia, it 
is puzzling that self-report measures of anhedonia, which primarily emphasize 
pleasure and positive emotionality, should differ from laboratory measures of 
affective responses to positive stimuli. One possibility is that these different 
classes of measures do not actually assess the same construct. Self-report 
measures may be broadly divided into two groups, depending on whether they 
are asking an individual to report on current emotions (as is common during 
laboratory tasks), or non-current emotions (as is common for trait and clinical-
symptom inventories) (Robinson & Clore, 2002b). Importantly, these different 
types of measures may rely on distinct types of cognitive processing; reports of 
current emotions assess primarily interoceptive ability to report on momentary 
affective experience, whereas non-current inventories may require either 
episodic memory retrieval in cases of common symptom inventories, or affective 
forecasting in response to hypothetical scenarios, as is the case with some trait 
measures. The former is subject to retrospective bias, while the latter requires 
patients to engage in affective forecasting regarding hypothetical future scenarios 
(e.g., “how much would you enjoy a walk in park on a sunny day?”). In both 
cases, measures of recent symptoms and/or prediction of enjoyment in 
hypothetical scenarios may be only modestly related to laboratory measures of 
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in-the-moment-experience (Robinson & Clore, 2002a), especially in patient 
populations (Strauss & Gold, 2012). Consistent with these concerns, recent 
studies employing ecological-moment-assessment (EMA) techniques have 
observed only moderate relationships between EMA reports and trait-inventories, 
especially in patient populations (Solhan, Trull, Jahng, & Wood, 2009). These 
results suggest that despite the high test-retest reliability of trait and clinical 
instruments, they may possess relatively modest predictive validity for 
momentary affective experience in the laboratory.  
 
Assessment of Anhedonia: More than a feeling?  
 If laboratory-based ratings of positive stimuli and symptom inventories do 
not assess different constructs, which is most clinically relevant? One way to 
address this question is to operationalize anhedonia as a behavioral pattern 
characterized by withdrawal and isolation, rather than an affective state. From 
this perspective, anhedonia is the end-result of debilitating cycle in which 
individuals predict that they will not enjoy things that they used to enjoy, and on 
the basis of this prediction, cease to engage in them. As a direct consequence of 
this behavioral withdrawal, the individual begins to notice that their life is 
increasingly devoid of things they enjoy, and (erroneously) conclude that this is 
because they no longer have the capacity to enjoy things. This formulation views 
anhedonia as a primarily behavioral symptom, and may require behavioral 
measures that are sensitive to motivation.  
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  Taken together, the reviewed evidence suggests that while diagnosis of 
anhedonia assesses both motivation and experience of pleasure, current 
questionnaire and laboratory measures of anhedonia have largely emphasized 
the latter; there are few laboratory studies that have directly assessed motivation 
in MDD.  In laboratory settings, a number of studies have found evidence for 
diminished responsiveness to positively-valenced stimuli, but the work of Bylsma 
et al., suggests that this may reflect a general affective flattening. Moreover, it 
remains unclear how closely related measures of affective responses to 
positively-valenced stimuli are to the construct of hedonic capacity. Importantly, 
the lack of group differences on the sweet-taste test raise potential doubts as to 
whether or not depression is associated with a specific deficit in the capacity to 
feel pleasure, at least at the level of basic sensory experience.    
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CHAPTER III 
NEUROBIOLOGICAL MECHANISMS OF ANHEDONIA  
   
 In contrast to clinical studies of anhedonia, which have attended primarily 
to hedonic aspects of reward processing, preclinical research has focused 
heavily on sub-components such as reward motivation, learning, anticipation, 
hedonic response and satiety.  These various aspects of reward have been 
linked to a variety of brain regions, neural circuits and neurotransmitters. These 
include the neurotransmitter dopamine and opioid neuropeptides, sub-cortical 
structures such as the basal ganglia and striatum (particularly the nucleus 
accumbens (NAcc), ventral pallidum (VP), ventral tegmental area (VTA), 
substantia nigra (SN), amygdala and hippocampus, as well as cortical regions 
such as the ventromedial prefrontal cortex (vmPFC), encompassing aspects of 
orbital frontal cortex (OFC), anterior cingulate cortex (ACC) and medial prefrontal 
cortex (mPFC). In this section I review the neural mechanisms that underlie 
motivational aspects of reward processing as well as evidence to support the role 
of this neurocircuitry in the pathophysiology of MDD. 
 
Motivation and the Mesocorticolimbic DA system 
 Located within the pars compacta of the substantia nigra (SNpc) and VTA, 
DA neurons give rise to three ascending pathways: the nigrostriatal, mesolimbic 
and mesocortical pathways, as depicted in figure 1. The nigrostriatal pathway 
terminating in the dorsal caudate and putamen is heavily implicated in motor 
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control, and habit learning. The mesolimbic pathway terminates in the ventral 
striatum (including the NAcc), the amygdala and hippocampus, and is most 
closely associated with associative learning, reward motivation and 
reinforcement. The mesocortical pathway projects to cortical regions, including 
dense innervation of the ACC, with additional terminals in orbital frontal cortex, 
medial prefrontal cortex and the insula. This third pathway is strongly associated 
with working memory, attention, and inhibitory control.  
 
Figure 1: Schematic illustration of dopamine projection pathways and circuitry regulating 
DA release in the human brain. DA firing rates are maintained at tonic levels in part due 
to steady-state inhibitory firing from the ventral pallidum. Excitatory projections from 
prefrontal cortex project, amygdala and hippocampus synapse on striatal targets, including 
the nucleus accumbens. The nucleus accumbens sends GABAergic projections to the 
ventral pallidum, suppressing VP inhibition of VTA, thereby facilitating phasic burst-
firing of VTA DA neurons. Note: Placement of structure labels is approximate. Amyg = 
amygdala; Caud = Caudate; DA = Dopamine; GABA = GABAergic projections; Glu = 
glutamatergic projections; Hipp = hippocampus; NAcc = nucleus accumbens; Put = 
Putamen; SN = substantia nigra; VP = ventral pallidum; VTA = ventral tegmental area 
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 Midbrain DA neurons exhibit two distinct modes of firing, referred to as 
“tonic” and “phasic” (Grace & Bunney, 1984). Tonic DA activity refers to steady-
state firing generated by intrinsic pacemaker-like characteristics of DA neurons. 
Phasic activity—also known as “burst firing”—involves a rapid series of action 
potentials that induce a rapid rise in extracellular DA at terminal projection 
targets.  As additionally outlined in figure 1, initiation of phasic activity requires 
excitatory signals from a variety of areas, including the prefrontal cortex, 
pedunculpontinetegmentum (PPt) and subthalamic nucleus (Floresco, West, 
Ash, Moore, & Grace, 2003; Futami, Takakusaki, & Kitai, 1995) (Smith & Grace, 
1992) as well as suppression of steady-state inhibitory signals arising from the 
NAcc and ventral pallidum (VP) (Sesack & Grace). 
 A key function of DA is to modulate the sensitivity of post-synaptic 
neurons to other types of input. In the striatum—the largest recipient of DA 
projections—DA may modulate the sensitivity of medium spiny neurons (MSN) to 
excitatory glutamatergic projections from prefrontal and limbic regions. As shown 
in figure 2, DA acts primarily on one of 5 post-synaptic G-protein coupled 
receptors, labeled D1-D5 (Cooper, 2003). These receptors are grouped into two 
“families”, described as D1-like (including D1 and D5 receptors) and D2-like (D2, 
D3 and D4 receptors). Upon receptor stimulation, Both D1-like and D2-like 
receptors interact with adenylate cyclase (AC) (Surmeier, Ding, Day, Wang, & 
Shen, 2007). D1-like receptor stimulation increases AC activity through coupling 
with either G alpha S or (Gα-s) G alpha olfactory (Gα-olf ), which results in 
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increased activation of protein kinase A (PKA) and subsequent phosphorylation 
of various intracellular targets. Recent evidence suggests that this intracellular 
pathway can result in increased responsiveness of MSNs to sustained release of 
glutamate, generating “up-states” (Surmeier, et al., 2007). In contrast, D2-like 
 
 
 
 
 
 
 
Figure 2: Schematic illustration of dopamine synapse on striatal medium spiny 
neuron. DA stimulation of D1-like receptors increases the activity of adenylate 
cyclase, while stimulation of D2-like receptors suppresses adenylate cyclase 
activity. DA may be removed from the synapse either by reuptake via the DA 
transporter or degradation by monoamine oxidase, resulting in the DA 
metabolite of homovanillic acid. Psychostimulants increase synaptic DA by 
blocking DAT function, while monoamine oxidase inhibitors block MAO 
activity and pramipexole inhibits DA autoreceptors. AC = adenylate cyclase; 
DAT = DA transporter; DOPA = 3,4-dihydroxyphenylalanine; HVA = 
homovanillic acid; MAO = monoamine oxidase; MAOI = monoamine oxidase 
inhibitor; MSN = medium spiny neuron; TH = tyrosine hydroxylase.    
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receptor binding results in decreased AC activity, thereby reducing the 
responsiveness of MSNs (“down states”) (Hernandez-Lopez, et al., 2000). Of 
note, due to their higher affinity for DA as well as their more centralized location 
on the post-synaptic membrane, D2-like receptors are often stimulated by tonic 
levels of DA release, whereas D1-like receptors are stimulated primarily during 
phasic DA release (Goto, Otani, & Grace, 2007).  
 Initial evidence for the role of DA in mediating motivation for rewards 
comes from the fact that 6-OHDA lesions of NAcc DA synapses do not impair 
hedonic liking expressions in rats (Berridge & Robinson, 1998). Similar effects 
have been found following the systemic administration of neuroleptic drugs—
acting primarily on DAergic sites— which also failed to alter liking responses 
(Kaczmarek & Kiefer, 2000; Parker & Leeb, 1994; Pecina, Berridge, & Parker, 
1997). Finally, DA burst-firing—which commonly occurs in response to 
unexpected rewards—ceases after the previously unexpected reward becomes 
predicted, despite the fact that the hedonic value of the predicted reward is 
presumably intact (Berridge, 2007; Schultz, 2006; Schultz, Dayan, & Montague, 
1997). Even more striking evidence comes from studies using mice that have 
been genetically engineered to be incapable of endogenous DA synthesis 
without the aid of daily L-DOPA administration (Zhou & Palmiter, 1995). 
Suspension of these L-DOPA administrations for a single day can result in the 
near-total depletion of DA in the brain. However, even these highly DA-depleted 
mice still favor sucrose-water over regular water, and demonstrated a morphine-
induced conditioned place-preference (Cannon & Palmiter, 2003; Hnasko, Sotak, 
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& Palmiter, 2005). Finally, studies have found that increasing DA shows no effect 
on liking behavior. Genetically modified mice that exhibit a knockdown of the 
Dopamine Transporter (DAT) gene, thereby resulting in increased extracellular 
DA, showed no alterations in liking responses (Pecina, et al., 1997). In sum, 
these findings provide clear evidence that DA function is neither necessary nor 
sufficient for hedonic liking responses to occur.   
 A second line of work has sought to demonstrate a pivotal role for DA in 
the motivation to pursue rewards, as indexed by overcoming response costs 
(Salamone, et al., 2007). As shown in figure 3, Salamone and colleagues 
developed experimental paradigms that evaluate an animal’s willingness to work 
for a given reward. These paradigms, described herein as “effort-based decision-
making” paradigms, include concurrent-choice tasks and progressive ratio tasks 
(Assadi, Yucel, & Pantelis, 2009). Initial studies employed a T-maze design, in 
which rats enter a T-shaped maze and made a choice between one arm of the 
maze containing a readily available food reward (Low-Cost/Low Reward, 
“LC/LR”), and another arm containing a larger food reward that was available 
only after climbing a barrier (High-Cost/High-Reward, “HC/HR”). Using this 
choice-paradigm, it was demonstrated that while control rats prefer the HC/HR 
option, rats with NAcc DA lesions or blockade of striatal D2 receptors show 
increased preference for the LC/LR option (Correa, Carlson, Wisniecki, & 
Salamone, 2002; Cousins, Atherton, Turner, & Salamone, 1996; Cousins & 
Salamone, 1994; Denk, et al., 2005; Salamone, et al., 2007).   
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 Convergent evidence was found during an operant response concurrent-
choice task, where rats must choose between eating freely-available, unpalatable 
“lab chow” (LC/LR option) or pressing a lever several times in order to receive a 
preferred food reward (HC/HR option). As with the T-maze paradigm, blockade of 
NAcc DA through either lesions of DA projection terminals with 6-OHDA will 
result in a reduced preference for the HR choice (Aberman & Salamone, 1999; 
Correa, et al., 2002; Cousins & Salamone, 1996; Hamill, Trevitt, Nowend, 
Carlson, & Salamone, 1999; Salamone, Correa, Mingote, & Weber, 2005; 
Salamone, et al., 1991). Additional studies have found that global blockade of DA 
using selective D1 or D2 receptor antagonists may also impair effort-based 
decision-making (Bardgett, Depenbrock, Downs, Points, & Green, 2009; Walton, 
et al., 2009), though selective impairment of phasic DA release does not (Zweifel, 
et al., 2009).  
 
 
 
 
 
 
 
 Figure 3: Schematic diagram of effort-based decision-making paradigms. 
Animals may choose between a smaller food reward that is readily available 
(LC/LR option) or a greater food reward that can only be obtained after 
climbing over a barrier (HC/HR option). Control rats choose the HC/HR 
option approximately 90% of the time, while DA depleted rats show a strong 
preference for the LC/LR option.  
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 A key aspect of these paradigms for translational psychopathology 
research is the fact that control animals choose HC/HR options approximately 
90% of the time, thereby suggesting that experimentally-induced increases in 
LC/LR choices can reasonably be interpreted as pathological in nature, rather 
than a minor shift in normative preferences. In addition, multiple control 
experiments have been performed to rule out possible confounding factors, such 
as alterations in the ability to engage in voluntary movement, or diminished 
understanding of reward contingencies. For example, in conditions where reward 
is removed entirely from the LC/LR option, or the paradigm is modified so that 
both LC/LR and HC/HR options require equal effort, NAcc DA depleted rats 
cease to differ from control animals (Denk, et al., 2005; Salamone, 1996). 
Additionally, one recent study confirmed that NAcc DA influences effort-
expenditure preferences even when controlling for differences in reward delay, 
as HC/HR options often require extra time to complete (Floresco, St Onge, 
Ghods-Sharifi, & Winstanley, 2008). These additional studies suggest that 
experimentally-induced preferences for LC/LR options are; 1) sufficiently 
abnormal to be construed as a pathological deficit in motivation, and 2) do not 
result from impaired understanding of choice contingencies, physical inability, or 
temporal delay. Taken together, these findings provide strong evidence for the 
role in DA as encoding the motivational aspects of reward processing, while 
being relatively uninvolved in the hedonic experience.  
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Evidence for DA Dysfunction in Depression 
 Given the robust associations between DA and reward motivation, it would 
be predicted that if motivational deficits are indeed an important feature of MDD, 
evidence for DAergic dysfunction should be detectable in patient samples. As 
with other neurotransmitters and biological systems, however, definitive support 
for DA dysfunction in MDD remains elusive. One challenge to uncovering the role 
of DA in MDD is that many studies have employed group designs with 
heterogeneous samples that are not limited to patients with anhedonic 
symptoms, much less specific motivational and consummatory subtypes. Such 
heterogeneity may mask group differences in DA function, as well as specific 
within-group associations between DA and anhedonia. This problem is worsened 
by the fact that assessment instruments for anhedonia are heavily weighted 
towards pleasure responses, which are unlikely to be strongly associated with 
DA function. Nevertheless, multiple studies support the hypothesis that 
abnormalities in DA are indeed common in patients with MDD, if not necessarily 
ubiquitous across all clinical presentations. 
Initial data supporting a role of DA in MDD comes from studies of DA 
turnover, which observed that individuals with MDD have decreased 
cerebrospinal fluid (CSF) levels of homovanillic acid (HVA), the primary 
metabolite of DA (Berger, et al., 1980; Lambert, Johansson, Agren, & Friberg, 
2000; van Praag, Korf, & Schut, 1973; Willner, 1983a). These studies suggest 
the presence of lowered basal DAergic tone in MDD. Additionally, 
pharmacological interventions that block or deplete DA can induce or deepen 
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depressive symptoms in currently depressed or remitted individuals (Bremner, et 
al., 2003; Hasler, et al., 2008; Ruhe, Mason, & Schene, 2007), further implicating 
DA dysfunction in MDD.  
In animal models of depression, several lines of evidence also support the 
role of DA dysfunction. The Flinders sensitive line (FSL), a genetic animal model 
of MDD, exhibit reduced basal concentrations of DA in the NAcc and slower rates 
of DA release in the NAcc as compared to Sprague-Dawley (SD) rats (Zangen, 
Nakash, Overstreet, & Yadid, 2001). One contributing cause of reduced 
extracellular DA concentrations in DA neuron terminal regions is altered firing 
patterns of midbrain DA neurons themselves. Consistent with this explanation, 
FSL rats have been observed to exhibit marked impairment in phasic burst firing 
(Friedman, et al., 2007) (for a review, see (Yadid & Friedman, 2008)). Another 
animal model of depression that implicates DA function is the post-
psychostimulant withdrawal model (Barr & Markou, 2005; Barr, Markou, & 
Phillips, 2002). This model is particularly relevant for research on DA in MDD, as 
it produces a significant number of symptoms associated with MDD (Markou, 
Kosten, & Koob, 1998) and results from direct manipulation of the DA system. 
Consistent with effort-expenditure deficits observed by Salamone and colleagues 
following NAcc DA blockade, psychostimulant withdrawal has been shown to 
reduce both NAcc extracellular DA levels (Weiss, Markou, Lorang, & Koob, 1992) 
and effort-expenditure for sucrose rewards during a progressive ratio task (Barr & 
Phillips, 1999).  
DA acting drugs, particularly D2 agonists, have antidepressant properties 
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in animal models of depression (for a review see (Gershon, Vishne, & Grunhaus, 
2007)). Indeed, a large number of studies have demonstrated that chronic 
administration of various classes of antidepressant medication show a common 
effect of increasing D2-like receptor binding or sensitivity in the NAcc, and 
increased psychomotor responses to psychostimulants (D'Aquila, Collu, Gessa, 
& Serra, 2000; Gershon, et al., 2007). Such effects are observed following 
chronic treatment with both tricyclic antidepressants and SSRIs, even though the 
acute effects of these agents are primarily mediated through serotonergic and 
noradrenergic mechanisms. Notably, however, the antidepressant effects of 
these agents can be blocked entirely by D2-like receptor antagonists. Finally, the 
selective serotonin-reuptake enhancer (SSRE) tianeptine has been shown to 
have robust antidepressant properties, a finding contrary to what would be 
expected if MDD were associated with a specific deficit in 5HT signaling (Kasper 
& McEwen, 2008). While the mechanisms that underlie the antidepressant 
properties of tianeptine are unclear, it is noteworthy that this compound has been 
shown to increase NAcc extracellular DA levels as well as DA turnover in rodents 
(Invernizzi, Pozzi, Garattini, & Samanin, 1992).  
In humans, pharmacological enhancement of DA signaling provides at 
least temporary antidepressant effects, and has been seen with DA agonists 
such as bromocriptine, piribedil, ropinirole and pramipexole (Bouras & Bridges, 
1982; Cassano, et al., 2005; Shopsin & Gershon, 1978; Sitland-Marken, Wells, 
Froemming, Chu, & Brown, 1990; Vale, Espejel, & Dominguez, 1971; Waehrens 
& Gerlach, 1981). DAT inhibitors nomifensine (Kapur & Mann, 1992), 
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methylphenidate (El-Mallakh, 2000), amineptine and bupropion also exhibit 
varying degrees of antidepressant effects, further highlighting the possible role 
DA in MDD (see section 5 for further review) (Kapur & Mann, 1992; Stahl, 2000).  
 Human neuroimaging studies of DA synthesis capacity have shown 
reduced L-DOPA uptake in MDD (Agren & Reibring, 1994). Moreover, studies 
exploring different sub-groups have found that L-DOPA alterations in the striatum 
are present in depressed individuals with flat affect or psychomotor slowing, but 
not depressed individuals without these symptoms (Bragulat, et al., 2007; 
Martinot, et al., 2001). Patients with reduced DA synthesis in Parkinson’s disease 
also show increased rates of MDD (Koerts, Leenders, Koning, Portman, & van 
Beilen, 2007).  These data suggest that reduced DA synthesis capacity may be 
linked to specific symptoms in MDD.   
Additional evidence of altered DA function in MDD comes from Positron 
Emission Tomography (PET) and Single Photon Emission Computed 
Tomography (SPECT) imaging of the DA transporter (DAT), where depression 
has been associated with both lower (Meyer, et al., 2001) and higher 
(Amsterdam & Newberg, 2007; Laasonen-Balk, et al., 1999; Yang, et al., 2008) 
DAT binding potential in the striatum. Of note, however, the one study that 
restricted its MDD patient sample to individuals with anhedonic symptoms 
reported decreased DAT binding (Sarchiapone, et al., 2006). Monoamine 
oxidase A, a metabolizing enzyme of DA and other monoamines has been 
shown to be elevated in MDD across multiple brain regions, suggesting one 
possible mechanism through which observed decreases in monoamine 
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transmission may occur during a depressive episode (Meyer, et al., 2006). 
Heightened activity of MAOA in MDD may partially explain the efficacy of MAO 
inhibitors, which likely lead to the increased availability of monoamines—
including DA—by returning MAOA activity to normative levels. 
Studies of DA receptor availability in MDD have to date produced mixed 
results. In some cases, increased striatal D2/D3 receptor binding has been 
shown to occur in heterogeneous depressed samples (D'Haenen H & Bossuyt, 
1994; Shah, Ogilvie, Goodwin, & Ebmeier, 1997), as well as in patient samples 
with specific symptoms of psychomotor slowing (Meyer, et al., 2006). This 
increase in D2/D3 receptor availability would appear to contradict animal data in 
which antidepressant responses are associated with increased D2-like binding in 
the striatum. The source of this discrepancy is unclear, but it may be noted that 
the patients in human studies were not medication naïve. Other studies using 
medication-naïve or medication-free patients have failed to identify group 
differences in striatal receptor binding (Hirvonen, et al., 2008; Parsey, et al., 
2001), while one additional small study showed variable changes in D2-like 
binding following treatment with SSRIs, with those showing increased binding 
showing more clinical improvement than those who did not (Klimke, et al., 1999). 
Taken together, these studies suggest a possible role of D2-like receptors in 
downstream effects of antidepressant treatment. However, the precise nature of 
the effect and how alterations in D2-like receptor availability may relate to DA 
function as a whole remains unclear. Moreover the use of heterogeneous 
samples, and limited exploration of specific symptoms, has precluded 
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examination of specific relationships between D2-like function and motivational 
anhedonia.  
As for D1-like receptors, a recent study of D1 receptors using PET-[11C]NNC-
112 found reduced D1-like receptor binding in the striatum bilaterally in a sample 
of individuals with MDD (Cannon, et al., 2009). Anhedonia as assessed by a sub-
scale of the IDS-C was not correlated with change in binding potential in the 
MDD group. However, as with other commonly used assessments of anhedonia, 
the anhedonia subscale from the IDS-C primarily emphasizes consummatory, 
rather than motivational aspects.   
 It is additionally worth noting that a proposed role for DA dysfunction in the 
pathophysiology of MDD is consistent with current etiological models that 
highlight interactions between genetic risk factors and stressful life events in the 
onset, maintenance and relapse of MDD (Caspi, et al., 2003; Hammen, 2005; 
Kendler, Karkowski, & Prescott, 1999; Kessler, 1997). Genetic studies have 
identified several polymorphisms related to DAergic function that increase risk for 
the development of depression. The most reliable of these findings is allelic 
variations in the DRD4 gene (Lopez Leon, et al., 2005) and D3 receptor gene in 
both unipolar and bipolar depression (Chiaroni, et al., 2000; Dikeos, et al., 1999). 
Additionally, the effects of chronic and acute stress are well known to have 
significant consequences on the DA system. Stress has been shown to increase 
glucocorticoid signaling (Holsboer, 2000), precipitate neuronal degeneration in 
the hippocampus (Sapolsky, 2000) and medial prefrontal cortex (McEwen, 2005; 
Radley, et al., 2006), decrease the availability of brain-derived neurotrophic 
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factor (BDNF) (Duman, 2009), and increase levels of pro-inflammatory cytokines 
in the brain (Dowlati, et al.; Maier & Watkins, 1998). Importantly, all of these 
modulations have direct influence on DA function. Glucocorticoids modulate firing 
of DA neurons (Piazza, Barrot, et al., 1996; Piazza, Rouge-Pont, et al., 1996), 
and regions that suffer glucocorticoid-mediated atrophy are key regulators of 
mesolimbic and mesocortical DA projection pathways (Arnsten, 2009; Lisman & 
Grace, 2005). BDNF has been shown to regulate VTA DA neurons (Conner, 
Lauterborn, Yan, Gall, & Varon, 1997), and alterations in BDNF can influence 
mesolimbic DA responses to reward and resiliency to stress (Berton, et al., 2006; 
Cordeira, Frank, Sena-Esteves, Pothos, & Rios).  Finally, increases in pro-
inflammatory cytokines can impact both the metabolism and synthesis of DA 
(Anisman, Merali, & Hayley, 2008) so as to result in reduced DA availability.  
 Taken together, the above studies provide evidence that 1) MDD is 
associated with compromised DA function, 2) manipulations of the DA system 
contribute to the actions of antidepressants and 3) alterations of DA function are 
often a downstream consequence of genetic and environmental risk factors, such 
as exposure to stress.  These positive findings are qualified by the presence of 
null findings, as well as the difficulty in interpretation associated with some of the 
studies. Notably, some of the findings appear specific to sub-populations of 
depressed individuals defined by the presence or absence of specific symptoms. 
This observation is consistent with the central claim that rigorous phenotypic 
description—such as distinct measures for motivational and consummatory 
aspects of reward— is crucial for reliable results with biological measures.  
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CHAPTER IV 
DEVELOPING A TRANSLATIONAL MODEL OF REWARD MOTIVATION  
 
To address the clear need to develop a laboratory-based measure in 
humans that could be used to assess motivational aspects of reward processing, 
I developed the Effort-Expenditure for Rewards Task (EEfRT or “effort”). The 
EEfRT paradigm is based on a concurrent choice paradigm devised by 
Salamone and colleagues to explore effort-based decision-making in rodents198. 
In designing this task, there were several considerations that were paramount.  
First and foremost, the goal of the task was to serve as a translational adaptation 
of preclinical effort-based decision-making tasks that could be used to enhance 
the relevance of these preclinical models to clinical research as well as to 
facilitate “back-translation” of findings from human studies toward the generation 
o novel experiments in animals. This “back-translatability” was viewed as being 
especially crucial, as it is critical aspect of animal model validation that is often 
neglected (Fernando & Robbins, 2012). Second, it was vital that the EEfRT was 
able to accurately assess individual differences in motivation to work for rewards, 
and not differences in actual or perceived ability to perform the work. For 
instance, early design ideas included asking participants to go up and down 
several flights of stairs in order to gain rewards, but there was concern that 
genuine differences in physical fitness would confound inferences about subject 
motivation. Similarly, cognitive effort challenges, such as arithmetic problems or 
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puzzles, which have been used in past studies (Shechter, Durik, Miyamoto, & 
Harackiewicz, 2011), can produce anxiety in subjects about their ability to 
perform the task, which can influence decision-making. Consequently, the effort 
requirements of the EEfRT focused on speeded manual presses in the form of 
button pressing, a form of effort that has been previously used to probe 
motivational systems in humans (Breiter, Aharon, Kahneman, Dale, & Shizgal, 
2001).  
 Given these considerations, the EEfRT was designed as a multi-trial 
game in which participants are given an opportunity on each trial to choose 
between two different task difficulty levels in order to obtain monetary rewards 
(Figure 4). For all trials, participants make repeated manual button presses within 
a short period of time. Each button press raises the level of a virtual “bar” viewed 
onscreen by the participant.  Participants are eligible to win the money allotted for 
each trial if they raise the bar to the “top” within the prescribed time period.  Each 
trial presents the subject with a choice between two levels of task difficulty, a 
‘hard task’ (HC/HR option) and an ‘easy task’ (LC/LR option). Successful 
completion of hard-task trials requires the subject to make 100 button presses, 
using the non-dominant little finger within 21 seconds, while successful 
completion of easy-task trials requires the subject to make 30 button presses, 
using the dominant index finger within 7 seconds. For easy-task trials, subjects 
are eligible to win the same amount, $1.00, on each trial if they successfully 
completed the task. For hard-task choices, subjects are eligible to win higher 
amounts that vary per trial within a range of $1.24 – $4.30 (“reward magnitude”).   
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Subjects are not guaranteed to win the reward if they completed the task 
for a given trial; some trials are “win” trials, in which the subject received the 
stated reward amount, while others are “no win” trials, in which the subject 
receives no money for completing the chosen task. To help subjects determine 
which trials are more likely to be win trials, subjects are provided with accurate 
probability cues at the beginning of each trial. Trials have three levels of 
probability: “high” 88% probability of being a win trial, “medium” 50% and “low” 
12%. Probability levels apply to both the hard task and the easy task, and there 
were equal proportions of each probability level across the experiment. Each 
level of probability appears once in conjunction with each level of reward value 
for the hard task. All subjects receive trials presented in the same randomized 
order.  
We note that the inclusion of a probability manipulation represents a 
departure from preclinical paradigms, which have focused on effort-expenditure 
alone (Cousins & Salamone, 1994; Walton, Bannerman, & Rushworth, 2002). 
There were several reasons why this manipulation was the included. The first 
was to improve the ecological validity of the EEfRT; positive events are rarely if 
ever guaranteed, and unanticipated setbacks can scuttle the pursuit of even 
mundane rewards in MDD patients. Second, preclinical data suggest that 
processing of probability information during cost/benefit decision-making is 
similarly dependent of mesolimbic DA function. Paralleling findings with effort, DA 
antagonism reduces tolerance for probability costs, shifting preference away from 
larger, uncertain rewards to guaranteed smaller rewards, while amphetamine 
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increases preference for larger, riskier rewards (St. Onge, Chiu, & Floresco, 
2010; St. Onge & Floresco, 2008) but see also (Zeeb, Robbins, & Winstanley, 
2009). These findings are consistent with theoretical models suggesting that 
mesolimbic DA encodes different types of response costs (e.g., effort and 
probability) in a similar manner (Phillips, Walton, & Jhou, 2007). Finally, the 
inclusion of probability, which effectively discounted the reward magnitude of the 
HC/HR option, helped to improve the sensitivity of the task for detecting 
individual differences.  
 
 
 
 
All trials of the EEfRT begin with a 1-second fixation cross, following a 5-
second choice period in which subjects are presented with information regarding 
the probability of receiving reward and the reward magnitude of the hard task. 
Subjects are told that if they do not make a choice within 5 seconds, they would 
be randomly assigned to either the easy or the hard task for that trial. After 
making a choice, subjects are then shown a 1-second “Ready” screen and then 
prompted to complete the task. Following task completion, subjects are shown a 
Figure 4: Schematic diagram of a single trial of the EEfRT. A. Trials begin with a 
1s fixation cue. B. Subjects are then presented with a 5s choice period where 
they are given information regarding the reward magnitude of the High Effort 
option, and the probability of receiving a reward. C. 1s “ready” screen. D. Subjects 
make rapid button presses to complete the chosen task and watch a virtual “bar” 
on the screen that fills up as they progress to their completion goal. E. Subjects 
receive feedback on whether they completed the task. F. Subjects receive 
feedback as to whether they received any money for that trial.  
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2 second feedback screen informing them that the task was successfully or 
unsuccessfully completed. If subjects successfully completed the task, then a 
second feedback screen appears for 2 seconds in which subjects were told 
whether they won money for that trial (reward feedback). In total, easy-task trials 
take approximately 15 seconds, whereas hard-task trials take approximately 30 
seconds.  
Subjects are told that they will receive a base-rate of compensation for 
their participation in the form of either money or course-credit. In addition, they 
are told that two of their win trials would be randomly selected at the end of the 
experiment as “incentive trials,” for which they would receive the actual amount 
won on those trials. Subjects are informed that they have twenty minutes to play 
as many trials as they can Since hard-task trials take approximately twice as 
much time to complete as easy-task trials, the number of trials that a subject is 
able to play depends in part on the choices that he or she makes. This means 
that making more hard-task trials toward the beginning of the experiment could 
reduce the total number of trials, which could in turn mean that a subject did not 
get a chance to play high-value, high-probability trials that might have appeared 
towards the end of the playing time. This trade-off is explained clearly to the 
subject. Importantly, subjects are not provided with any information regarding the 
distribution of trial types. The goal of this trade-off is to ensure that neither a 
strategy of always choosing the easy or the hard option could lead to an ‘optimal’ 
performance on the task. Finally, the complexity of variables (varying monetary 
reward levels, probability), do not lend itself to a formal calculation of an optimal 
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response selection, and subjects are required to make decisions within a brief 
amount of time. This was done to help ensure that subject decisions reflected 
individual differences in the willingness to expend effort for a given level of 
expected reward value. The EEfRT was programmed in Matlab (Matlab for 
Windows, Rel. 2007b. Mathworks Inc., Natick, MA) using the Psychtoolbox 
version 2.0.  
 
Methods 
Participants 
 61 participants (64% female) were recruited through Vanderbilt University 
and the community to participate in this study. Subjects were chosen from a 
larger sample of 324 undergraduates who were pre-screened using a brief self-
report measure of hedonic responsiveness, the Snaith-Hamilton Pleasure Scale 
(SHAPS) 58. This measure was used to ensure an appropriate range of trait 
anhedonia scores in our experimental sample. 
 
Study Procedure 
 Upon arriving to the lab, participants first reviewed a consent form and 
provided written consent. Participants were then asked to complete all self-report 
measures. After this, participants were provided with a series of task instructions. 
After participants read through the instructions, they were asked several simple 
questions to ensure they understood the task and its contingencies. Participants 
then played four practice trials. For the first two trials, the participant was 
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instructed to choose the easy and hard task respectively, in order to gain 
familiarity with the level of effort required for each task. For the last two practice 
trials, the subject was free to choose.  After completion of practice trials, the 
participant was asked if he or she had any questions.  If not, then the subject 
commenced playing for a timed period of 20 minutes. 
  
Measures 
 In addition to the EEfRT, several self-report measures of state and trait 
anhedonia were collected. The Chapman physical and social anhedonia scales 
(Chapman, et al., 1976) served as the primary trait measure for anhedonia.  
 
Data Reduction and Analysis 
Because subjects could only play for 20 minutes, the number of trials 
completed during that time varied from subject to subject (Mean trials completed 
= 54, SD = 4.74, Range = 47-69 trials). For consistency of analysis, only the first 
50 trials were used. Data were exported from Matlab into SPSS (SPSS for 
Macintosh, Rel. 16.0. 2008. Chicago: SPSS Inc.) for further analysis.  
 
Statistical Analysis  
Data were analyzed using two statistical approaches. The first approach 
used repeated measures ANOVA and correlations. For these analyses, mean 
proportions of hard-task choices were created for all subjects across each level 
of probability. Proportions of hard-task choices and responses to self-report 
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questionnaires were approximately normally distributed, and therefore parametric 
tests were used for inferential statistics.  
 The second approach used generalized estimating equations (GEE). GEE 
is a generalized regression model that is used to investigate continuous or 
logistic outcome variables in which the residuals are correlated (Zeger & Liang, 
1986). The term “Generalized” in this context means that different distributions 
(e.g. normal, dichotomous, Poisson) can be modeled through a link function.  
Importantly, GEE models allow for trial-by-trial modeling of both time-varying 
parameters (e.g., changes in reward value of the hard-task for each trial) as well 
as fixed effects (e.g., scores on anhedonia measures). The dependent measure 
was the dichotomous outcome of hard or easy task choice, and we used a binary 
logistic distribution to model the probability of choosing the hard-task. For all 
models, independent variables included probability, reward, expected value 
(reward magnitude X probability), trait anhedonia (Chapman) and gender. 
Separate models assessed the effects of trait anhedonia, and the interaction 
between trait anhedonia with probability level, reward magnitude and/or expected 
value.  
 
Effects of Fatigue During the EEfRT 
 An important requirement for the EEfRT is that it measure individual 
differences in motivation for rewards, rather than individual differences in ability 
or fatigue. The task was specifically designed to require a meaningful difference 
in effort between hard and easy-task choices while still being simple enough to 
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ensure that all subjects were capable of completing either task, and that subjects 
would not reach a point of exhaustion. Two manipulation checks were used to 
ensure that neither ability nor fatigue shaped our results. First, we examined the 
completion rate across all trials for each subject, and found that all subjects 
completed between 96%-100% of trials.  This suggests that all subjects were 
readily able to complete both the hard and easy tasks throughout the experiment. 
As a second manipulation check, we used trial number as an additional covariate 
in each of our GEE models.  
 
Results 
 
Main Effects of the EFFRT 
 Across the sample, subjects displayed significant variability in their 
willingness to expend effort for rewards, with proportion of HC/HR options 
ranging from a low of 16% to 75% of total choices (Figure 5). A Repeated 
Measures ANOVA found a significant main effect for probability level on the 
proportion of hard task choices, with higher probability trials levels associated 
with more hard-task choices (f(2,120) = 139.8, p < 0.001). Across all subjects, 
proportion of hard-task choices for medium probability trials were moderately 
correlated with proportion of hard-task choices for both high probability (r = 0.31, 
p < 0.05) and low probability trials (r = 0.31, p < 0.05). High probability and low 
probability trials were uncorrelated (r = -0.02, p = ns). We also found a main 
effect of gender, with men making more hard-task choices than women (f(1,59) = 
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3.9, p = 0.05). Consequently, gender was included as a covariate in all 
subsequent analyses.  
 
 
 
 
 
 
 
Figure 5: Distribution of the proportion of HC/HR options made by a sample of 
healthy volunteers, indicating significant variability in the willingness to expend 
effort for rewards.  
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Effects of Trait Anhedonia on EEfRT Performance 
 Partial correlations (controlling for gender) between proportion of HC/HR 
options and self-report measures demonstrated a modest association between 
willingness to expend effort across all trial and self-reported trait anhedonia (r =   
-0.30, p <0.05) (Figure 6).  
 
 
 
 To further characterize the association between Chapman Anhedonia 
scores and EEfRT performance, we tested a single GEE model that included the 
Chapman scores, trial probability level, hard-task reward value, expected value 
Figure 6: Association between the Chapman Anhedonia Scales and overall 
proportion of HC/HR choices during the EEfRT. r = -0.30, p < 0.05.  
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(EV), trial number and gender as covariates. All reward parameters (probability, 
reward magnitude and EV) were significant predictors of choice behavior (p’s < 
0.05) as was trial number (b = -0.008, p < .05), indicating some fatigue over the 
course of the task. This model also revealed a significant effect of Chapman 
Anhedonia scale, even when controlling for trial-wise variables throughout the 
task (b = -0.02, p <0.05).  
 
Discussion 
 The present study had two goals: 1) to validate the EEfRT as a novel 
effort-based decision-making task that could serve as an objective measure of 
individual differences in reward motivation; and 2) to explore the utility of the 
EEfRT in predicting trait anhedonia. In accordance with our first hypothesis, we 
found that individuals showed substantial variability in their willingness to expend 
greater effort for differing levels of reward magnitude and probability. This is 
consistent with well-validated self-report questionnaires, which also suggest 
significant variability in reported levels of motivation for various types of rewards 
(Costa & McCrae, 1992; Duckworth, Peterson, Matthews, & Kelly, 2007; 
Duckworth & Quinn, 2009; Duckworth, Quinn, Lynam, Loeber, & Stouthamer-
Loeber, 2011). 
 For the second aim, we found a significant main effect of trait anhedonia 
on EEfRT performance, such that individuals with higher levels of reported-trait 
anhedonia chose fewer HC/HR options. However, the effect size of this 
relationship was relatively modest. While this association provides some 
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preliminary validation of the task, an important limitation of this analysis is that 
the Chapman Anhedonia Scales assesses a subject’s beliefs about whether she 
generally enjoys various experiences. As discussed in chapters II and III, there is 
growing evidence from both clinical and preclinical studies to suggest that 
motivational and hedonic responsiveness rely on separable neural systems, and 
may therefore not necessarily be expected to show strong linear associations.  
  We also found a main effect of gender across all analyses, with women 
consistently making fewer hard-task choices than men. Given that the EEfRT is a 
computer-based task that emphasizes physical performance, it is conceivable 
that the task is gender-biased. Additional studies will determine whether these 
observed differences stem from particular design elements of the EEfRT, or 
reflect a true gender disparity in normative effort-based decision-making.  
 In sum, this initial study unveiled a novel effort-based decision-making 
task, the ‘EEfRT’, as a means of exploring effort-based decision-making in 
humans. As an objective measure of individual differences in reward motivation, 
we believe the EEfRT may provide a useful tool for studying motivational 
anhedonia and its relationship to DA functioning.  
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CHAPTER V 
 
DOPAMINERGIC BASIS OF EFFORT-BASED DECISION-MAKING IN 
HUMANS 
 
 To further demonstrate the utility of the EEfRT as a translational paradigm 
of reward motivation in humans, I next sought to demonstrate its association with 
neurobiological substrates that have been found to mediate motivation in animal 
studies. As reviewed in Chapter III, a wealth of preclinical data implicates DA as 
a crucial neurochemical for cost/benefit decision-making.  Attenuation of DA 
signaling—especially in the NAcc—produces a behavioral shift away from 
HC/HR options (Cousins & Salamone, 1994; Salamone, et al., 2007), while 
enhancement of DAerigc tone increases willingness to work for rewards 
(Bardgett, et al., 2009). Similar effects have been observed for studies of risk-
related choice, with DA blockade associated with reduced willingness to choose 
riskier (but larger) rewards (St Onge & Floresco, 2009), suggesting that alteration 
of DA neurotransmission may exert its influence primarily by helping the 
organism overcome response costs—such as effort requirements, probability of 
receipt or temporal delay— that may discount the face-value of the reward 
magnitude (P. E. Phillips, M. E. Walton, & T. C. Jhou, 2007; Salamone, et al., 
2007).   
Recently, two studies in humans reported similar effects of DAergic 
attenuation and potentiation on effort-based decision-making. In a sample of 
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smokers, dietary depletion of catecholamine precursors resulting in transient 
reduction of DA availability decreased the willingness to expend effort for 
cigarettes during a progressive ratio task (Venugopalan, et al., 2011). 
Conversely, a study performed using the EEfRT during a placebo-controlled, d-
amphetamine challenge paradigm found that administration of d-amphetamine 
increased participants’ willingness to make HC/HR choices, particularly under 
conditions of low probability (Wardle, Treadway, Mayo, Zald, & de Wit, 2011).  
 We evaluated individual differences in DA function by measuring 
stimulant-induced change in D2/D3 receptor availability using a placebo-
controlled, d-amphetamine challenge paradigm in conjunction with a dual-scan.  
 
Methods 
Participants 
25 participants (52% female) were studied as part of an ongoing 
investigation of individual differences in striatal and extrastriatal DA function.  All 
participants were medically and psychiatrically healthy adults, age 19 to 29. 
Following initial screening, subjects were given an interview of their medical 
history and a structured psychiatric interview (SCID-NP). Subjects were excluded 
if they had any history of substance abuse, current tobacco use, and use of 
psychostimulants (excluding caffeine) more than twice in the subject’s lifetime or 
at all in the past 6 months, any psychotropic medication for the past 6 months 
other than occasional use of benzodiazepines for sleep, history of psychiatric 
illness, significant medical condition, or any condition which would interfere in 
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PET or MRI studies (e.g., extreme obesity, claustrophobia, cochlear implant, 
metal fragments in eyes, cardiac pacemaker, neural stimulator, and metallic body 
inclusions or other metal implanted in the body, pregnancy). Participants were 
also excluded if they had any contra-indications for receiving d-amphetamine 
(abnormal EKG, hypertension). Subjects who reported recent use (within the last 
6 months) of tobacco products were excluded. Subjects who reported recent use 
of alcohol or marijuana were allowed to continue in the study, provided that they 
abstained from any use of these substances until the study was complete.  Urine 
drug screens were used to confirm drug abstinence over the course of the study. 
A summary of subject demographics is presented in table 1. 
 
Study Design 
 The goal of the current study was to evaluate how variability in DA 
function was associated with individual differences in cost/benefit decision-
making preferences. Subjects completed 3 testing sessions. The first two 
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sessions involved completing a PET scan while receiving either a pill placebo or 
d-amphetamine challenge. During the 3rd testing session, subjects completed the 
EEfRT as described previously. Importantly, subjects were not under the 
influence of d-amphetamine when completing the EEfRT. This design allowed us 
to assess how differences in DA system responsivity were associated with basal 
variation in cost/benefit preferences.  
 
PET Image Acquisition  
 All PET images were acquired using [18F]fallypride ((S)-N-[(1-allyl-2-
pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2,3-dimethoxybenzamide), a 
substituted benzamide with very high affinity to D2/D3 receptors (Mukherjee, 
Christian, Narayanan, Shi, & Collins, 2005).  The use of [18F]fallypride in the 
present context is critical in that unlike other D2/D3 ligands, [18F]fallypride allows 
stable estimates of D2-like binding in both striatal and extrastriatal regions 
(Christian, et al., 2004; Mukherjee, et al., 2002). It thus provides a unique ability 
to simultaneously examine human DA function in both cortical and striatal areas 
involved in cost/benefit decision-making.  Previous work has demonstrated good 
test-retest reliability of [18F]fallypride measurements of non-displaceable binding 
potential BPND —a computed estimate of the number of available D2/D3 
receptors—in both striatal and prefrontal areas (Mukherjee et al., 2002). Each 
subject received two [18F]fallypride scans: the first was a baseline placebo scan, 
and the second scan occurred on a separate day and was performed while the 
subject received a 0.43 mg/kg oral dose of d-amphetamine. Scans were not 
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counterbalanced for several reasons. First and foremost, our study was designed 
to assess individual differences, and thus it was optimal to keep all aspects of the 
study design constant across subjects.  Counterbalancing would require 
additional statistical control, and would lower statistical power.  Moreover, 
counterbalancing would impair maintenance of blinding, as most subjects 
receiving d-amphetamine during the first scan would be aware of receiving 
placebo for the second scan.  Finally, conducting the d-amphetamine scans on 
the first scan day requires additional time between scan days, which is 
problematic for scheduling female participants, who were scheduled so as to 
ensure that both scans were conducted in the early follicular phase of their 
menstrual cycle for both scanning days. All PET scans were acquired on a GE 
Discovery STE system manufactured by General Electric (Easton, CT, USA) 
located at Vanderbilt University medical center. [18F]Fallypride was produced in 
the radiochemistry laboratory attached to the PET unit, following synthesis and 
quality control procedures described in US Food and Drug Administration IND 
47,245. Scans were timed to start 3 hours after d-amphetamine administration, 
which was timed to coincide with the period of peak plasma d-amphetamine. 3-D 
emission acquisitions scans were performed following a 5.0 mCi slow bolus 
injection of [18F]fallypride (specific activity greater than 3000 Ci/mmol). Serial 
scans were started simultaneously with the bolus injection of [18F]fallypride and 
were obtained for approximately 3.5 hours, with two 15-minute breaks for subject 
comfort. Low dose CT scans were collected for attenuation correction prior to 
each of the three emissions scans.  
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PET Image Processing 
 Each subject’s serial PET scans were first corrected for motion across 
scanning periods using a mutual information-based rigid body algorithm (Maes, 
Collignon, Vandermeulen, Marchal, & Suetens, 1997; Wells, Viola, Atsumi, 
Nakajima, & Kikinis, 1996).  Regional D2/D3 BPND was calculated on a voxel-wise 
basis using the full (four compartment) reference tissue method (Lammertsma, et 
al., 1996), with cerebellum chosen as the reference region because of its relative 
lack of D2/D3 receptors (Hall, et al., 1994). The full model was selected over the 
simplified reference region model due to concerns that have previously been 
raised about applying the simplified model to high affinity ligands (Votaw, Kessler, 
& de Paulis, 1993). Using the full reference region method, near perfect (r = 0.99) 
correlations have been found with modeled estimates using a metabolite corrected 
plasma input function (R. M. Kessler, et al., 2000). Although this approach is 
slower computationally than the simplified (three parameter) tissue reference 
method, the two methods show nearly identical estimates of binding potential, and 
have demonstrated excellent convergence of modeled fits in regions with both high 
and low D2/D3 receptor levels. Voxelwise kinetic modeling was executed using 
Interactive Data Language (RSI, Boulder, CO).  
 Each participant’s BPND image was aligned with their T1-weighted MRI 
based on co-registration of the weighted average of the PET dynamic scans to 
the MRI using a mutual information based rigid body algorithm (Maes, et al., 
1997; Wells, et al., 1996).  Prior to group analyses, a composite binding potential 
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image was created for each PET scan, and warped to MNI space using a non-
rigid body co-registration (Rohde, Aldroubi, & Dawant, 2003).  The transformation 
matrix from this warping was then applied to the BPND statistical parametric maps 
(SPM) in order to bring them into MNI space. Using the ‘imcalc’ routine as 
implemented in SPM5, voxel-wise maps of the percent change in D2/D3 BPND 
(%∆BPND) across the amphetamine- and placebo-day scans were created for 
each subject, providing an index of stimulant-induced DA responsivity. Voxelwise 
%∆BPND maps were inspected for any regions showing %∆BPND > 50%, which 
could arise due to misalignment across scan days.  One subject showed 
evidence of this in a few voxels near the boundary of the putamen and insula.  
Because the insula was among the areas showing statistically significant effects, 
we analyzed the data both with and without these voxels for the subject included 
in the analysis.  The results were significant in both cases, and we report the 
lower magnitude effect (with those voxels excluded) below.   
 
Statistical Methods 
 The effects of different levels of reward magnitude, probability and expected 
value (reward magnitude X probability) on the likelihood of making an HC/HR 
choice during the EEfRT were estimated using a single Generalized Estimating 
Equation (GEE) (Zeger & Liang, 1986). The relationship between individual 
differences in choice behavior and variability in %∆BPND was assessed on a voxel-
wise basis using a multiple regression analysis as implemented in SPM5, with 
proportion of HC/HR choices as the primary independent variable and subject age 
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and gender included as covariates. We tested for regions showing both positive 
and negative correlations with proportion of HC/HR options. Whole-brain correction 
for multiple comparisons was achieved using a cluster-extent correction procedure 
as implemented in SPM5. Only results surviving cluster-correction (pcluster < 0.05) 
are reported. Because [18F]fallypride BPND values exhibit significant variability 
across different regions (e.g., striatum vs. PFC), we used variance estimates at the 
voxelwise level rather than the pooled variance used in typical parametric analyses 
(Dagher, 1998).  Once significant clusters were identified, cluster-wise %∆BPND 
values were extracted and entered into SPSS 19.0 for further analysis. 
 
Planned Analyses  
 Given the results of our prior study suggesting that the direct effect of d-
amphetamine on EEfRT task performance was strongest for low (12%) probability 
trials (Wardle, et al., 2011), our first analysis was to identify associations between 
%∆BPND and the proportion of HC/HR choices during low probability trials. This 
condition requires willingness to pursue rewards when facing both effort and 
probability costs. This was followed-up by an exploration of the relationship 
between %∆BPND and proportion of HC/HR choices averaged across all probability 
levels, which examines individual differences in responses to effort costs alone.  
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Results 
Behavioral Results 
 All subjects chose a combination of HC/HR and LC/LR options (mean 
proportion of HC/HR choices = 0.43, SD = 0.11). A single GEE model was used 
to test the effects of reward magnitude, probability and expected value on choice 
behavior. Consistent with results described in Chapter IV, each of these variables 
were significant, independent predictors of choice behavior: reward magnitude: b 
= 0.69, p = 0.001; probability: b = 1.03, p = 0.021; expected value: b = 1.16, p = 
0.016. 
 
DA Sensitivity and EEfRT Performance: Low Probability Trials Only  
 Based on our prior work indicating that the effects of d-amphetamine on 
EEfRT task behavior were strongest for low probability trials (in which subjects 
have to overcome costs related to both effort and low probability), I first explored 
associations between d-amphetamine-induced DA responses and proportion of 
HC/HR choices during low probability trials only. This analysis revealed a strong 
positive association between %∆BPND in left caudate (x = -8, y = 10, z = 14, peak 
Z-score = 3.45, k = 71, pcluster< 0.001) (all coordinates are given in the imaging 
space of the Montreal Neurological Institute, MNI), primarily encompassing the 
pre- and post-commissural dorsal portion of this structure. In addition, HC/HR 
choices were positively correlated with %∆BPND within a prefrontal network 
comprised of bilateral ventromedial prefrontal cortex (vmPFC) (x = 20, y = 42, z = 
-18, peak Z-score = 3.67, k = 80, pcluster< 0.001), left ventrolateral prefrontal 
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cortex (vlPFC) (x = -48 y = 18, z = 6, peak Z-Score = 3.13, k = 44, pcluster = 
0.005). We also observed a positive association between %∆BPND in the left 
inferior temporal gyrus and HC/HR choices (x = -56, y = -18, z = -22, peak Z-
score = 4.13, k = 41, pcluster = 0.018) (see table 2, figure 7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Relationship between proportion of HC/HR choices during low 
probability (12%) trials and stimulated DA release. A. SPM depicting voxels 
showing significant positive correlation between stimulated DA release in left 
caudate and vmPFC and proportion of HC/HR choices during low probability 
trials. B. SPM depicting voxels showing significant positive correlation 
between stimulated DA release in left vlPFC and temporal cortex and 
proportion of HC/HR choices during low probability trials. C. Scatterplot of 
proportion HC/HR choices during 12% trials and stimulated DA release in left 
caudate C. Scatterplot of proportion HC/HR choices during 12% trials and 
stimulated DA release in vmPFC. Visualization threshold reflects correction for 
multiple comparisons, t > 2.5, k >35.  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For each of these identified regions, the association between DA responses and 
HC/HR choices was unchanged when the baseline BPND was included in the 
model as a covariate, thereby ruling out the possibility that the observed 
associations were due to individual differences in basal D2/D3 binding as 
opposed to %∆BPND.  
 In order to assess the magnitude of stimulant-induced change in D2/D3 B 
PND in these indentified areas, we tested the effects of d-amphetamine on BPND 
within these regions. D-amphetamine produced a significant decrease in BPND in 
left caudate (-5.6%), left vlPFC (-7.6%), left temporal cortex (-4.2%), but not in 
vmPFC, which showed a non-significant decrease of -1.9% (see table 3). No 
regions showed a significant inverse correlation between %∆BPND and the 
proportion of HC/HR trials during the low probability trials.  
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DA Sensitivity and EEfRT Performance: All Trials 
 In addition to exploring just the low probability trials, we also examined 
whether there were any associations between DA responses and the proportion 
of HC/HR choices averaged across all probability levels. When we tested for 
positive associations, we did not identify any clusters that survived correction for 
multiple comparisons. In the negative direction, overall proportion of HC/HR 
choices showed a strong inverse relationship with %∆BPND in bilateral anterior 
insula (Left: x = -24, y = 22, z = 10, peak Z-score = 5.55, k = 206; pcluster< 0.001; 
Right: x = 44, y =10, z = -2, peak Z-score = 3.41, k = 50 pcluster = 0.022), 
suggesting that greater DA sensitivity in these regions was associated with fewer 
HC/HR (i.e., more LC/LR) choices throughout the task (see table 2, figure 8). As 
above, we assessed whether the association between DA responsivity and 
HC/HR choices was affected by the inclusion of baseline BPND and found that it 
was not. We also explored the effects of d-amphetamine on BPND in the insular 
regions, and found that it produced significant decreases in BPND in both left and 
right insula, resulting in a -9.2% and -6.8% change, respectively (see table 3).   
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ROI Analysis Across Probability Conditions 
 Given that distinct patterns of association emerged when examining 
HC/HR choices during low probability trials only as compared to HC/HR choices 
averaged across all probability levels, I extracted estimates of %∆BPND for all 
Figure 8: Relationship between proportion of HC/HR choices and insula DA 
release. A. SPM depicting voxels showing significant inverse correlation 
between DA release in bilateral insula and overall proportion of HC/HR 
choices. B. Scatterplot of DA release in left insula and proportion of HC/HR 
choices. C. Scatterplot of DA release in right insula and proportion of HC/HR 
choices. Visualization threshold reflects correction for multiple comparisons, t 
> 2.5, k >35.  NB: Regression analyses are still significant when high-influence 
subject is removed (left: b = -0.64, p = 0.001; right: b = -0.53, p = 0.014). 
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identified regions and examined their association with the proportion of HC/HR 
choices for each level of probability (controlling for age and gender). In addition, I 
tested whether there was a statistically significant difference between 
correlations at different probability levels for each ROI (see table 4).  
 
  
 Consistent with the voxel-wise approach, regions identified in our low-
probability analysis (left caudate, vmPFC, left vlPFC and left temporal cortex) 
showed significant differences in r-values between the high and low probability 
conditions. The same was true for r-values compared between the low- and 
medium-probability conditions for all extrastriatal areas.  In contrast, regions 
identified in the analysis of all trials (right and left insula) show no significant 
differences in r-values across any of the three probability levels. 
 
Discussion 
 The present study provides novel evidence linking individual differences in 
DA responsivity to variation in human cost/benefit choice behavior. Positive 
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associations between DA function and willingness to expend effort for larger 
rewards were strongest during low probability trials, when subjects had to 
overcome both effort and probabilistic response costs. Two of the regions 
showing this association—the striatum and vmPFC—are known to be critically 
involved in multiple forms of cost/benefit decision-making (Botvinick, Huffstetler, 
& McGuire, 2009; Croxson, Walton, O'Reilly, Behrens, & Rushworth, 2009; Hare, 
O'Doherty, Camerer, Schultz, & Rangel, 2008; Kable & Glimcher, 2009; McGuire 
& Botvinick, 2010). Interestingly, we also observed a strong inverse correlation 
between willingness to bear effort costs and DA responses in the bilateral insula. 
This pattern of findings suggests an important regional specificity in the 
relationship between DAergic function and individual differences in cost/benefit 
choice behavior. 
 In animal models, robust evidence indicates that DA-releasing agents help 
increase an organism’s tolerance of costs that may discount the face value of a 
reward, such as effort required, (Salamone, et al., 2007), probability of receipt (St 
Onge & Floresco, 2009), or temporal delay (Wade, de Wit, & Richards, 2000). 
Further emphasizing the role of DA in specifically mitigating response costs, 
research has demonstrated that when effort or probability costs are low (e.g., 
effort requirements of an FR1 schedule), the impact of DA manipulation is 
minimal. However, the consequences of either DA enhancement or attenuation 
increase dramatically as response requirements rise and reward probabilities 
decline (Salamone, Wisniecki, Carlson, & Correa, 2001; St Onge & Floresco, 
2009). Similarly in humans, the effects of d-amphetamine administration on 
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processing of effort and probability costs during the EEfRT are greatest for low-
probability trials (Wardle, et al., 2011).  
 Consistent with these prior preclinical and human findings, we observed 
the strongest positive association between DA sensitivity and willingness to work 
more for rewards during low-probability trials, when subjects were required to 
overcome the maximum combination of effort and probabilistic response costs. In 
this analysis, we observed that DA responses in left striatum, as well as left 
vlPFC and bilateral vmPFC were associated with a higher proportion of High 
Effort choices. This corroborates prior findings suggesting that striatal DA 
function is critical for effort-related behavior (Salamone, et al., 2007).   
 In contrast to striatal DA, the role of DA within both vmPFC and vlPFC has 
received relatively less attention. Some evidence suggests that vmPFC DA 
function may be similarly required to maintain effortful responding for rewards 
(Cetin, Freudenberg, Fuchtemeier, & Koch, 2004), as well as motivated 
performance of cognitively-demanding tasks (Winstanley, et al., 2010). More 
broadly, the vmPFC has been heavily implicated in both human and non-human 
primate studies as a key region involved in value-based decision-making, in 
which the individual must choose across multiple cost/benefit options (Kable & 
Glimcher, 2009; Noonan, et al., 2010). Similarly, a number of studies also 
support a role for vlPFC in reward-based decision-making (McGuire & Botvinick, 
2010; Sakagami & Pan, 2007). The current findings suggest that DA function 
within these regions contributes to individual differences in cost/benefit decision-
making. 
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 This study also identified the bilateral insula as a region where greater DA-
responsivity was associated with more LC/LR (i.e., fewer HC/HR) options across 
all levels of probability. By averaging across probability levels, this analysis 
explored individual differences in sensitivity to effort-expenditure alone. To my 
knowledge, the effects of DA depletion or enhancement in this region on 
motivated behavior have not been explored in animals. However, both lesion and 
neuroimaging studies highlight the importance of this structure in mediating 
motivation and cost/benefit decision-making. Functional magnetic resonance 
imaging (fMRI) studies of reward learning have repeatedly highlighted bilateral 
anterior insula as an area involved in processing response costs (Knutson, Rick, 
Wimmer, Prelec, & Loewenstein, 2007; Kuhnen & Knutson, 2005) as well as 
reward-dependent prediction errors (Pessiglione, Seymour, Flandin, Dolan, & 
Frith, 2006), which are generally thought to reflect phasic DA activity (Schultz, 
2007). Neural activity in the insula during anticipation of losses has been found to 
predict subsequent acquisition of loss-avoidance decision-making (Samanez-
Larkin, Hollon, Carstensen, & Knutson, 2008), and individuals with lesions to 
anterior insula show less sensitivity to changes in expected value during risk-
based decision-making (Weller, Levin, Shiv, & Bechara, 2009). Of particular note, 
a recent fMRI study exploring effort-based decision-making in humans found that 
increased bilateral insula activation was a strong predictor of choosing a Low 
Effort option (Prevost, Pessiglione, Metereau, Clery-Melin, & Dreher, 2010). 
While these studies do not directly assess DA function, it seems reasonable to 
speculate that these activation patterns may reflect—in part—DAergic signaling. 
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The human insula receives relatively rich DA innervation (Gaspar, Berger, 
Febvret, Vigny, & Henry, 1989) and expresses both D1-like and D2-like receptors 
(Hurd, Suzuki, & Sedvall, 2001). Support for this interpretation comes from 
another fMRI study in which subjects viewed positively and negatively-valenced 
cues predicting pleasant or aversive tastes (pictures of chocolate or moldy 
strawberries) while receiving either a pill placebo or oral dose of sulpride, a 
potent D2/D3-antagonist. Interestingly, sulpride blunted BOLD responses in the 
ventral striatum to chocolate pictures (positive cues), but also blunted BOLD 
responses in the anterior insula to moldy strawberry pictures (aversive cues) 
(McCabe, Huber, Harmer, & Cowen, 2011). These results support the 
interpretation of the present findings, that DA function in the striatum and vmPFC 
are associated with approach-related responses (increased motivation), while DA 
function in the insula may be associated with aversion. On the whole, these data, 
taken together with the current findings, raise the intriguing possibility that the 
insula plays a key role in processing response costs, and that DA signaling may 
contribute to this function. 
 Several limitations of this study warrant mention. First, while the analytical 
approach was informed by a previous study exploring the effects of d-
amphetamine on EEfRT performance (Wardle, et al., 2011), the current study did 
not examine the effects of d-amphetamine on EEfRT behavior in this sample; this 
would be of interest, but would address a distinct question from the focus of the 
present work. A second potential concern is that the D2/D3 receptor ligand used 
in this study, [18F]fallypride, is somewhat less sensitive to striatal DA release than 
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[11C]raclopride (Morris & Yoder, 2007), which may have contributed to identifying 
fewer positive associations between EEfRT performance and DA responses in 
striatal regions than might be expected given past animal studies 
(e.g.(Salamone, et al., 2007)). Nevertheless, studies have consistently indicated 
that [18F]fallypride is consistently able to detect significant d-amphetamine-
induced displacement within the striatum (Cropley, et al., 2008; Morris & Yoder, 
2007; Riccardi, et al., 2006; Slifstein, et al., 2010) and the magnitude of this 
release has repeatedly been found to show meaningful correlations with 
behavioral variables (Buckholtz, Treadway, Cowan, Woodward, Benning, et al., 
2010; Buckholtz, Treadway, Cowan, Woodward, Li, et al., 2010; Woodward, et 
al., 2011). Another issue is the observation that between 12%-50% of subjects 
appeared to show negative %∆BPND, depending on the region evaluated. 
Negative %∆BPND indicates an increase in D2/D3 receptor availability following 
d-amphetamine, which is inconsistent with the predicted effects of the drug. 
However, the presence of negative %∆BPND is common in past PET imaging 
studies across different ligands and regions, making it unlikely to reflect purely 
methodological error (Abi-Dargham, Kegeles, Martinez, Innis, & Laruelle, 2003; 
Drevets, et al., 2001; Leyton, et al., 2002; Martinez, et al., 2003; Volkow, et al., 
1997). More likely, this reflects individual variability in the duration and magnitude 
of amphetamine responses, which would be consistent with studies of reported 
subjective effects (de Wit, Uhlenhuth, & Johanson, 1986).  It is for this reason, 
however, that we interpret our data as reflecting DA “sensitivity” or “responsivity”, 
rather than just DA release. We also note that the lack of counterbalancing in our 
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design could have impacted %∆BPND if the novelty of the first scan day 
differentially caused DA release relative to the second scan day, which would 
reduce the magnitude of calculated d-amphetamine BPND displacement. It is also 
theoretically possible that the administration of [18F]fallypride during the first scan 
may have had effects on BPND that carried over to the second scan, though this 
seems unlikely given the sub-pharmaceutical dose used.   Finally, there have 
been some questions regarding the ability of [18F]fallypride to detect d-
amphetamine-induced displacement of BPND in extrastriatal regions, particularly 
cortical areas (Cropley, et al., 2008; Slifstein, et al., 2010).  However, a careful 
review of these studies indicates that d-amphetamine does in fact show expected 
decreases in [18F]fallypride BPND across multiple areas, but variability is high in 
cortical regions, which diminishes the ability to detect a statistically significant 
effect of d-amphetamine in studies with modest samples.  
 In sum, this study provides further evidence linking variation in human DA 
function with cost/benefit decision-making in humans, and extends the results of 
the prior findings by demonstrating a distinct relationship with individual 
differences.  This is a crucial step in validating animal models of DA function and 
effort-related behavior, and extends the translational value of these preclinical 
paradigms by demonstrating that they may be successfully translated to human 
paradigms.  
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CHAPTER VI 
Motivational Anhedonia in Major Depressive Disorder 
 
 Having established the EEfRT as a translational measure of individual 
differences in motivation that was sensitive to inter-subject variability in DAergic 
function, the final aim of this dissertation is to test whether DA-linked motivational 
deficits are associated with MDD. To test this hypothesis, this final study 
recruited a sample of MDD patients and matched controls and compared their 
willingness to expend effort for reward as assessed by the EEfRT.    
 
Methods 
Participants  
20 individuals diagnosed with MDD (14/20 female) and 15 healthy controls 
(9/15 female) participated. All participants were community volunteers who either 
responded to online recruitment advertisements or were referred from the 
Vanderbilt University Department of Psychiatry Mood Disorders Program 
outpatient clinic. Following initial screening, subjects were given an interview of 
their medical history and a structured psychiatric interview (SCID-P) (First, 
Spitzer, Gibbon, & Williams, 2005) and completed the Beck Depression Inventory 
II (BDI-II) (Beck, et al., 1996) and the Chapman Anhedonia Scales (Chapman, et 
al., 1976). For individuals in the MDD group, subjects were required to meet 
criteria for a current major depressive episode (MDE). Subjects were excluded if 
they met criteria for bipolar disorder, psychotic and schizoaffective disorders, 
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current substance abuse, past stimulant abuse, or past substance dependence. 
MDD subjects were also excluded for any current or past use of prescription 
drugs that act on DA (e.g., amphetamines, methylphenidate, l-dopa). Of the 20 
participants in the MDD group, 17 subjects were on an antidepressant 
medication at the time of the study (15 SSRI alone, 2 SNRI alone). Additionally, 8 
of the 20 subjects in the MDD group met criteria for a co-morbid anxiety disorder 
as assessed by the SCID.  
Subjects in the control group were excluded if they met criteria for any 
current or past Axis I disorder other than specific phobia, past adjustment 
disorder, or past substance abuse of non-stimulants. Control participants were 
also excluded if they exhibited significant trait-anhedonia despite not meeting 
clinical criteria for an Axis I disorder as determined by a score on the Chapman 
Anhedonia Scales that was two-standard deviations higher than published 
normative data for this instrument (Chapman, et al., 1976). This exclusion was 
based on the results described in Chapter IV, showing that elevated trait 
anhedonia in a non-patient sample may reduce willingness to expend effort for 
rewards, and resulted in the exclusion of one potential control subject. No control 
subjects were on any form of psychotropic medication at the time of the study. 
 
Measures 
 All subjects performed the Effort-Expenditure for Rewards Task (EEfRT or 
“effort”) as described previously and completed the Beck Depression Inventory II 
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(BDI-II) (Beck, et al., 1996) and the Chapman Anhedonia Scales (Chapman, et 
al., 1976). 
 
Statistical Analyses 
 Statistical analysis of choice behavior during the EEfRT was performed 
using Generalized Estimating Equation (GEE) models. The use of GEE is 
advantageous for the EEfRT, in that it can simultaneously model time-varying 
parameters (e.g., trial-wise changes in reward magnitude of the HC/HR option) 
as well as time-invariant parameters (e.g., estimates of stimulated DA release or 
MDD status). The use of GEE models is especially beneficial for the current 
study as they offer greater statistical power than traditional ANOVAS, which 
could compensate for the relatively smaller sample size of the current study as 
compared to the community sample described in Chapter IV. GEE models were 
implemented in SPSS 19 (IBM Armok, NY). The dependent measure was the 
dichotomous outcome of HC/HR or LC/LR choice, and we used a binary logistic 
distribution to model the probability of choosing the HC/HR option. Consistent 
with our prior analytical approach using the EEfRT, all GEE models included 
reward magnitude of the HC/HR option, probability and expected value (reward 
magnitude x probability). Separate models were computed to test the effects of 
group on HC/HR choices, as well as interactions between group and 
reinforcement variables (reward magnitude, probability and EV).  All models 
included trial number as a nuisance covariate to control for possible effects of 
fatigue over the course of the task. For between-group analyses, models also 
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included any demographic variables where groups showed significant 
differences. For within-group individual differences analyses (e.g., using the 
Chapman scales), sex was included as a covariate, as sex has been shown 
previously to be a significant predictor of EEfRT task performance in individual 
differences analysis.  
 
Results 
Sample Characteristics 
 Subject demographics and clinical variables are included in table 5. The 
depressed and control groups did not differ in terms of sex (X2 = .38, p = .537), or 
age (t33 = -.839, p = .41), but did differ in years of education (t33 = 3.00, p = .005), 
with the control subjects having approximately 2 more years of education on 
average. Subjects in the MDD group reported significantly higher depressive 
symptoms on the BDI-II (Mean = 24.6, SD = 9.25) than controls (Mean = 2.83, 
SD = 3.65) (t26.2 = -9.57, p < .001). MDD patients also reported significantly 
higher scores on the Chapman Anhedonia Scales (Mean = 37.05, SD = 15.86) 
as compared to controls (Mean = 11.87, SD = 7.50) (t28.6 =  -6.23, p < .001).  
 
EEfRT Trial Completion Rates 
 For both the MDD and control groups, all subjects chose a mix of HC/HR 
trials and LC/LR trials. There was no difference in the percentage of trials 
successfully completed by MDD patients (Mean = 99.4%, SD = 0.19%) or 
controls (Mean = 99.5%, SD = 0.15%) (t33 = .144, p = 0.89) 
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Results of GEE Models 
 We tested six independent models GEE models. Each model included all 
experimental task variables, including reward magnitude, reward probability, 
expected value, and trial number. Because of group differences in years of 
education, all between-group models included years of education as a covariate. 
For within-group, individual difference models, gender was added as a covariate.  
 Model 1 tested for main effects of Group on preference for HC/HR options, 
and found that compared to controls, MDD patients were significantly less likely 
to make HC/HR choices (b = -0.79, p < 0.001) (see figure 9). The effect of group 
remained a significant predictor even when symptoms of psychomotor slowing—
as assessed by SCID—were included as a covariate in the model (p < 0.001), 
indicating that the results were not explainable by depression-related differences 
in psychomotor speed.  
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 In model 2, we tested for the presence of an interaction between Group 
and Reward Magnitude, and found a significant interaction (b = -0.379, p = 
0.012).  In follow-up within-group analyses, we found that while reward 
magnitude was a significant predictor of HC/HR choices for both groups, its effect 
was larger for controls (b = 0.694, p < 0.001) than for MDD patients (b = 0.437, p 
< 0.001).  This suggests that the magnitude of the reward associated with the 
HC/HR option was more strongly predictive of choosing the HC/HR option in 
controls than in MDD patients.  
 Model 3 tested for an interaction between Group and Probability level. We 
observed a significant interaction between MDD patients and controls (b = -0.23, 
p = 0.038) such that probability was a stronger predictor of choice behavior for 
controls (b = 0.484, p < 0.001) then for patients (b = 0.361, p < 0.001).  
 In model 4, we tested for an interaction between Group and expected 
value, but did not find evidence for an interaction (b = -0.17, p = 0.399). However, 
while this interaction term was not significant, the expected value predictor 
showed a similar pattern to both reward magnitude and probability, such that it 
was a stronger predictor for the control group (b = 1.44, p = 0.03) as compared to 
the MDD group (b = -0.61, p < 0.001). 
 In model 5, we performed an individual differences analysis within the 
MDD group to see if EEfRT performance was related to symptom severity (BDI-
II) and course of illness. In an initial model, we found that duration of the current 
MDE predicted significantly fewer HC/HR choices (b = -0.014, p < 0.001), while 
BDI-II scores were predicted more HC/HR choices (b = 0.027, p < 0.001). These 
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effects were both present when each of these predictors was included 
independently.  We also note that sex was a significant predictor in this model, 
with men choosing more HC/HR choices than women. 
 
  
 
 
 
 
 
 
 
 
 
 
  
  
 Given the unexpected direction of the relationship between BDI-II scores 
and EEfRT choices, in model 6 we followed up with item-level analysis of BDI-II 
items related to reward anticipation (item 2) and reported enjoyment (item 4). We 
found that reduced anticipation was inversely associated with HC/HR choices (b 
= -0.15, p < 0.001), while the opposite was true for deficits in enjoyment (b = 
Figure 9: Mean proportion of HC/HR choices on the EEfRT for MDD patients 
and matched controls. 
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0.51, p < 0.001), suggesting that specific MDD symptoms may be differentially 
associated with EEfRT performance.    
  
Discussion 
 In this final study, we found evidence that patients with MDD show 
motivational anhedonia as indexed by an objective, translational effort-based 
decision-making task. Individuals with current MDD were less willing to expend 
effort for the opportunity to earn larger monetary rewards as compared to healthy 
controls. This supports a growing body of evidence suggesting that motivation 
may be an especially crucial aspect of altered reward processing in MDD (Clery-
Melin, et al., 2011; Sherdell, Waugh, & Gotlib, 2011). It may also help explain the 
success of behavioral activation treatments for MDD, which specifically target 
motivational symptoms (Dimidjian, et al., 2006).  
 In addition to differences in willingness to expend effort for rewards, we 
found that patients showed less sensitivity to information about the reward 
magnitude and probability of a win when making their choices.  Prior studies 
have found associations between depression and sensitivity to reward probability 
(Forbes, Shaw, & Dahl, 2007; Gradin, et al., 2011; Pizzagalli, et al., 2008). This 
reduced capacity for integrating information about reward probability when 
making effort-related choices may be related to previously reported cognitive 
vulnerabilities regarding the prediction and expectancy of positive future events 
in MDD (Abramson, Metalsky, & Alloy, 1989). Despite these interactions with 
both probability and reward-magnitude, there was no interaction between group 
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and expected value. That said, while the interaction term was not significant, the 
expected value predictor did follow a similar pattern, such that it was a stronger 
predictor for controls as compared to patients.  
 Within the MDD group, we observed several associations between the 
EEfRT and clinical variables. First, duration of the current MDE predicted fewer 
HC/HR choices, even when controlling for current symptom severity. This may 
suggest that motivational deficits are associated with a poorer course of MDE. 
Although the causal direction of this relationship remains to be elucidated, it is 
interesting to note that cognitive vulnerability models of depression have posited 
that helplessness and hopelessness are causally associated more pronounced 
motivational deficits as well as a longer course of illness (Abramson, et al., 1989; 
Abramson, Seligman, & Teasdale, 1978). Unexpectedly, we additionally 
observed an overall positive association with current MDE symptom severity as 
indexed by the BDI-II and HC/HR choices. Using an item-level analysis, we found 
that reduced anticipation of positive future events was associated with less 
willingness to work for rewards, while the opposite was true for deficits in reward 
consummation. This may suggest that effort-mobilization is primarily linked to 
symptoms related to reward expectancy—consistent with prior reports (Sherdell, 
et al., 2011)—and highlights the presence of distinct sub-components of 
anhedonia. However, given limitations in the reliability of individual items, this 
analysis should be interpreted with caution. Replication studies will be required to 
further clarify the relationship.  
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 The present study possesses several limitations. First, the requirement of 
speeded button-presses could affect choice behavior in some patients with 
psychomotor slowing. However, this seems unlikely given that patients and 
controls showed equal completion rates and controlling for psychomotor 
retardation did not alter the results.  A second limitation of the current study is the 
inclusion of depressed individuals who were not free of antidepressant 
medications.  Given known interactions between serotonin and DA, it is possible 
that SSRI medications may have influenced the current results. However, 
preclinical studies of SSRI effects on reward processing are mixed, with evidence 
to suggest that SSRIs both potentiate (Deslandes, Pache, Buckland, & Sewell, 
2002; Muscat, Papp, & Willner, 1992) and attenuate (Hoebel, Hernandez, 
Schwartz, Mark, & Hunter, 1989) reward function, and that these effects may 
depend on whether an animal is in a depressive state (Markou, Harrison, 
Chevrette, & Hoyer, 2005). Given these inconsistent findings it is unlikely that 
medication status alone could explain group differences in EEfRT task 
performance. Moreover, our results are consistent with significant prior evidence 
that SSRI treatments fail to address symptoms related to motivation and 
anhedonia in MDD (Nutt, et al., 2007; Shelton & Tomarken, 2001). Finally, our 
control sample was screened to rule out high-levels of trait anhedonia, which 
may limit the specificity of our findings to MDD, as opposed to anhedonic traits.  
 In sum, the current findings demonstrate that reduced motivation and 
altered cost/benefit decision-making may be a crucial aspect of anhedonic 
symptoms. Additionally, the success of this translational approach highlights the 
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importance of incorporating preclinical models of reward processing into the 
conceptualization and assessment of clinical symptoms. Such measures may 
ultimately facilitate the development of a more objective nosology of reward-
related deficits in MDD.  
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CHAPTER VII 
SUMMARY AND GENERAL DISCUSSION 
 
 In this final section, I will begin by summarizing the arguments and 
empirical data described above, and then conclude with a general discussion, 
including the limitations of the present work as well as implications for treatment.  
 The guiding principle of this dissertation has been the need to identify sub-
components of symptoms in MDD that may be tied to distinct neural circuits, with 
the ultimate goal of improving psychiatric nosology (Akil, et al., 2010). To this 
end, I have focused on the role of motivation for rewarding events in the clinical 
presentation of anhedonia in MDD, and its possible relationship to alterations in 
the mesocorticolimbic DA system. As outlined in chapter III, this neurotransmitter 
system has a long been associated with both reward processing and MDD, but 
its precise role in these phenomena are still being elucidated. From animal 
models, significant evidence has accrued to suggest that DA is specifically 
involved in the predictive value, incentive salience, and motivating properties of 
rewards (Berridge, 2007; Salamone, et al., 2007; Schultz et al., 1997). However, 
clinical measures of anhedonia (interview, laboratory and self-report), have 
generally neglected to assess these aspects of reward processing. 
Consequently, the focus of this dissertation has been to develop a laboratory-
based measure that could be used to explore individual differences in reward 
motivation (as indexed by willingness to work for them) and test hypotheses 
80 
regarding the role of mesocorticolimbic DA function in motivation as well as the 
effects of clinical depression.  
 In Aim 1, I outlined the rationale for the design for the EEfRT and 
demonstrated the utility of this paradigm as a tool for assessing meaningful 
individual differences in motivation to spend effort for rewards among subjects. 
This task was then tested in a pilot sample of Vanderbilt undergraduates and 
community volunteers where it was found that individuals exhibited significant 
variability in their willingness to work for monetary rewards, and that some of this 
variance was attributable to self-reported levels of trait anhedonia. While this 
latter association was statistically significant, the effect size was moderate (r = -
0.30).  The absence of a stronger correspondence between reported hedonic 
responses and reward motivation is consistent with past studies exploring 
different sub-components of reward deficits (Strauss & Gold, 2012). Moreover, 
preclinical models suggest that neural systems encoding incentive salience and 
subjective pleasure are dissociable, albeit interacting. Consequently, it would be 
reasonable to predict that measures of reward motivation and hedonic 
responsiveness would be expected to show a non-zero positive association, 
without necessarily being very strong. This is also in keeping with behavioral 
reports in humans and animals demonstrating that various forms of behavioral or 
pharmacological manipulations can separably influence the motivational and 
hedonic properties of a given stimulus (Litt, Khan, & Shiv, 2010; Tindell, Smith, 
Berridge, & Aldridge, 2009).  
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 In Aim 2, we used the EEfRT to explore DAergic correlates of individual 
differences in motivation using a dual-scan PET imaging protocol on and off a d-
amphetamine challenge. Consistent with preclinical studies that heavily implicate 
ventral striatal DA function in motivation, we found that heightened DA responses 
to amphetamine in this region were associated with greater willingness to tolerate 
effort and probabilistic response costs. Somewhat surprisingly, we also observed 
an inverse association between DA release in the insula and EEfRT 
performance, such that greater DA predicted less desire to work for rewards. To 
my knowledge, no preclinical study has directly tested the role of insular DA 
function in the context of reward motivation. However, a number of functional 
neuroimaging studies have identified a role for the insula in the processing of 
responses costs and aversive stimuli and outcomes (Prevost, et al., 2010; 
Samanez-Larkin, et al., 2008), which may be modulated by pharmacological 
manipulation of DA (McCabe, et al., 2011). This finding is especially interesting 
given the multiple neuroimaging studies implicating the role of the insula in 
depression and anxiety (Mitterschiffthaler, et al., 2003; Paulus & Stein, 2006; 
Stein, Simmons, Feinstein, & Paulus, 2007; Strigo, Simmons, Matthews, Craig, & 
Paulus, 2008). 
 Finally, in Aim 3, I used the EEFRT paradigm to assess the role of 
motivational deficits in MDD. From this study, it was observed that MDD patients 
were less motivated for monetary rewards than controls, were less sensitive to 
reward information when choosing whether to expend more or less effort, and 
that the magnitude of these deficits were associated with the duration of the 
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current episode, which may indicate that motivational symptoms become more 
pronounced over time. This study suggests that anhedonia in depression does 
not simply reflect a reduced capacity to experience pleasure, and underscores 
the role of DA-linked motivational processing in MDD, which is consistent with 
prior evidence highlighting alterations in DA circuitry as part of the pathology of 
the disorder (Kumar, et al., 2008; Pizzagalli, et al., 2009l; Tremblay, et al., 2005). 
 Taken together, the results of these three studies stress the importance of 
addressing heterogeneity in the presentation of anhedonia, with the specific 
recommendation of identifying behavioral and neurobiological markers of 
“motivational anhedonia” as well as “consummatory anhedonia”. In keeping with 
our primary set of predictions, we observed that individual differences in 
willingness to work were associated with DA function and the presence of MDD. 
Importantly, these findings included a specific association with DA function the 
striatum, thereby extending preclinical models of effort-based decision-making 
and ventral striatal DA function. As a result, the present work serves to enhance 
the relevance of these animal paradigms for research in clinical populations.  
 It is interesting to note, however, that while positive associations between 
DA responsivity and willingness to expend effort for rewards were observed only 
during the low probability trials, MDD patients did not appear to be specifically 
sensitive to reward probability. Rather, MDD patients showed an overall 
decrease in the willingness to expend effort across all three probability levels. 
Importantly, the only region to show a strong association between DA function an 
effort-choice across all 3 probability conditions was the insula, where DAergic 
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function was inversely related to willingness to work for rewards. This finding is 
particularly novel as no prior study has suggested the presence of this type of 
inverse relationship between individual differences in DA function and motivation 
or salience of rewards. Crucially, this suggests that DA may have directly 
oppositional roles in cost/benefit decision-making depending on the region of the 
brain engaged. Although not currently believed to play a central role in reward 
processing, the insula is well positioned to influence effort-based decision-
making. In addition to direct DAergic input (Gaspar, et al., 1989), the insula 
exhibits reciprocal connections with the extended circuitry known to be involved 
effort-based decision-making, including the anterior cingulate (Augustine, 1996) 
the amygdala (Jasmin, Burkey, Granato, & Ohara, 2004; Reynolds & Zahm, 
2005), vmPFC (Ongur & Price, 2000), and the ventral striatum (Reynolds & 
Zahm, 2005).  Given the presence of fMRI studies suggesting that the insula may 
be involved in the anticipation of monetary losses, coupled with its known role in 
the representation of internal affective states (Craig, 2002, 2009; Naqvi & 
Bechara, 2009; Paulus & Stein, 2006; Phan, Wager, Taylor, & Liberzon, 2002), it 
seems plausible that DAergic signaling in the insula plays a specific role of 
encoding and predicting stimulus costs associated with rewards (Prevost, et al., 
2010; Samanez-Larkin, et al., 2008). This function of the insula is especially 
intriguing in the context of decades old theoretical models that low expectancy for 
positive outcomes is a key factor in the development of depression (Abramson, 
et al., 1989; Abramson, et al., 1978; Alloy, Peterson, Abramson, & Seligman, 
84 
1984). Our data suggest that insular DA function might reflect a novel substrate 
underlying this critical cognitive vulnerability.  
 
Implications for Treatment 
 The ultimate goal of improving our understanding of neurobiological 
mechanisms is to improve treatment.  If the assessment of “motivational 
anhedonia” is improved, this could potentially serve as a key predictor of 
treatment response to specific types of behavioral or biological therapies shown 
to alter motivational systems. We do not believe that these treatments will 
necessarily work for all cases of depression, but suggest that they may be 
particularly effective for treatment-resistant depressions involving significant 
motivational anhedonia. This form of tailored treatment is the primary means of 
utilizing our enhanced knowledge of neurobiology to improve clinical outcomes, 
but it is dependent on detailed phenotypic description to be successful.  
 Behavioral activation (BA) provides a potential example of a specific 
psychotherapeutic technique that might be particularly appropriate in cases with 
motivational anhedonia. Initially developed as a component of Cognitive 
Behavioral Therapy (CBT), Behavioral Activation (BA) differs primarily in its 
conceptualization of patient cognitions as a ruminative behavior (Dimidjian, et al., 
2006). The goal of treatment is to help the patient identify when they are 
engaging in rewarding and non-rewarding behaviors, and to help the patient 
make behavioral choices that are likely to increase exposure to positively 
reinforcing experiences.  
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 Initial evidence suggests that by emphasizing an increase in motivated 
behaviors, BA may surpass CBT, particularly with clients diagnosed with co-
morbid personality disorders (Coffman, Martell, Dimidjian, Gallop, & Hollon, 
2007). Moreover, BA also includes specific techniques that address symptoms of 
decisional anhedonia. In one such technique, the therapist encourages the 
patient not to wait until the patient “feels like” engaging in a reward activity, 
thereby circumventing MDD-related impairments in reward decision-making due 
to lack of motivation (Martell, Addis, & Jacobson, 2001).  
 Recent evidence from neuroimaging studies also suggests that BA may 
specifically target the reward system. Whereas fMRI studies have shown that 
treatment response to CBT results in a progressive decrease in amygdala 
sensitivity to negative stimuli (Siegle, et al., 2006), successful treatment with BA 
led to increased BOLD responses of the striatum during reward anticipation 
(Dichter, et al., 2009). Additionally, specific techniques used in BA treatments 
also address components of decisional anhedonia.  
 In terms of pharmacological treatments, the exploration of tailored 
treatments for individuals experiencing motivational anhedonia using DA-active 
pharmacotherapies is recommended. This includes psychostimulants, DA 
agonists, and the NE/DA reuptake inhibitor bupropion.  Of the current FDA 
approved antidepressant drugs with DA-acting properties, bupropion is the most 
widely used in clinical practice. However, the pharmacological profile of 
bupropion is complex, and its effects on reward processing in animals and 
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humans may rely on a variety of mechanisms, some of which are still not entirely 
known.  
 It is well established that bupropion has little direct effect on 5HT function 
(Stahl, et al., 2004). Several studies exploring bupropion occupancy of DAT at 
clinical doses have reported occupancy rates ranging from 14%-26% in the 
striatum (Kugaya, et al., 2003; Learned-Coughlin, et al., 2003; Meyer, et al., 
2002), which are relatively low as compared to standard SERT occupancy rates 
of SSRIs (80%) or DAT occupancy of reinforcing psychostimulants (>50%) 
(Volkow, et al., 1995; Volkow, et al., 1997; Volkow, et al., 1998). These findings 
suggest that bupropion’s direct ability to increase synaptic DA levels through 
blockade of DAT may account for only some of its antidepressant effects. 
However, more recent work has also shown that bupropion increases the activity 
of the intracellular vesicular monoamine transporter 2 (VMAT2) protein, which 
may enhance extracellular DA by increasing available DA in presynaptic pools 
(Rau, et al., 2005). Bupropion may also exert regionally-specific influence over 
DA function through its action as an inhibitor of the norepinephrine transporter 
(NET), which is the primary transporter of DA in prefrontal regions. Finally, more 
recent work has suggested that bupropion decreases the activity of nicotinic 
acetylcholine receptors, which play a role in the effects of bupropion on 
psychomotor symptoms in MDD (See (Dwoskin, Rauhut, King-Pospisil, & Bardo, 
2006) for a review).   
 Preclinical studies have suggested that bupropion may be a superior 
treatment for symptoms of motivational anhedonia. Rats treated with bupropion 
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demonstrate decreased immobility time during the forced swim test and tail 
suspension tests (Cryan, et al., 2001; Cryan, et al., 2004) and showed greater 
willingness to work for food rewards during a progressive ratio task (Bruijnzeel & 
Markou, 2003). Moreover, the influence of bupropion was blocked via 
administration of both D1-like and D2-like receptor antagonists, suggesting that 
effects of bupropion were partially mediated through DAergic mechanisms 
(Paterson & Markou, 2007). Additionally, rats treated with either chronic or acute 
doses of bupropion show a reduced threshold for intracranial self-stimulation of 
the posterior lateral hypothalamus (Paterson, 2009; Paterson, Balfour, & Markou, 
2007). Similarly, bupropion enhanced responding to a conditioned reinforcer 
(Palmatier, et al., 2009), although a separate study reported a bupropion-induced 
decrease in responding for sucrose (Reichel, Linkugel, & Bevins, 2008). The 
latter result is contrary to what would be expected, given the findings of 
(Bruijnzeel & Markou, 2003) and highlights the complex effects of the bupropion 
on reward processing.  Interestingly, bupropion- mediated enhancement of 
conditioned reinforcers in the study by Palmatier et al. was ameliorated by 
Prazosin, an α2-NE receptor antagonist, suggesting that bupropion’s effects on 
reinforcement may also rely on noradrenergic mechanisms.  
In addition to bupropion, psychostimulants, including dexamphetamine, 
methylphenidate and modafinil, have also been explored as both monotherapy 
and adjunctive treatment options for MDD. Results from these studies have not 
been encouraging (particularly in the case of monotherapy), although the majority 
of studies using psychostimulants were conducted several decades ago, before 
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either DSM criteria or the Feighner criteria were in place (for reviews, see (Orr & 
Taylor, 2007) and (Candy, Jones, Williams, Tookman, & King, 2008)), and fail to 
meet current methodological standards for clinical trials. More recently, however, 
interest has reemerged in the utility of psychostimulants as an adjunctive therapy 
for specialized populations. In patients with advanced terminal illness, where 
tolerance and abuse potential are less of a concern, psychostimulants have 
shown a positive response, though few of these studies were placebo-controlled 
(Orr & Taylor, 2007). Similarly, in elderly populations, which often show less 
responsiveness to traditional antidepressants (Paykel, et al., 1995; Reynolds et 
al., 1999) and exhibit higher rates of suicidality (Lebowitz, et al., 1997), 
citalopram augmentation with methylphenidate produced a positive and rapid 
treatment response (Lavretsky & Kumar, 2001). Finally, DA agonists such as 
bromocriptine, ropinirole and pramipexole also exhibit antidepressant properties 
(Cassano, et al., 2005; Corrigan, Denahan, Wright, Ragual, & Evans, 2000; 
Sitland-Marken, et al., 1990). In addition to treating depressed patients, 
pramipexole has also been shown to be successful in treating anhedonic and 
depressive symptoms in patients with Parkinson’s disease, an illness associated 
with both loss of DA function and elevated rates of depressive illness (45%) 
(Lemke, 2008; Lemke, Brecht, Koester, Kraus, & Reichmann, 2005). 
Overall, head-to-head clinical trials between DA-acting agents and other 
pharmacotherapies have revealed strikingly similar response rates in the case of 
bupropion and pramipexole, (Chouinard, 1983; Coleman, et al., 1999; Corrigan, 
et al., 2000; Croft, et al., 1999; Kavoussi, Segraves, Hughes, Ascher, & 
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Johnston, 1997; Mendels, et al., 1983; Thase, et al., 2005; Weihs, et al., 2000; 
Weisler, et al., 1994). For psychostimulants, response rates are usually 
significantly worse than other alternatives (Candy et al., 2008; Taylor & Orr, 
2007).  However, the potential role of DA-acting drugs as a superior treatment for 
anhedonic symptoms has received some empirical support. Bupropion has 
shown to be more effective at treating symptoms related to motivational and 
consummatory anhedonia (Bodkin, Lasser, Wines, Gardner, & Baldessarini, 
1997; Tomarken, Dichter, Freid, Addington, & Shelton, 2004). In a large-sample 
review of treatment records of 910 patients receiving outpatient pharmacotherapy 
for depression, Jamerson and colleagues (2003) reported that patients receiving 
bupropion sustained release (SR) showed significant improvement of symptoms 
related to reduced interest, energy and loss of libido as compared to placebo 
(Jamerson, Krishnan, Roberts, Krishen, & Modell, 2003). Additionally, bupropion 
is often used to counter-act specific side effects of SSRIs (Nutt, et al., 2007), 
which may include reduced responsiveness to rewards and positive experience 
(McCabe C, 2009; Price, et al., 2009; Shelton & Tomarken, 2001). A recent 
meta-analysis of DA-acting antidepressant treatments suggests that they 
enhance overall quality-of-life in individuals with MDD (IsHak, et al., 2009). These 
findings are not only promising in terms of treatment options, they also further 
underscore the importance of tailoring DA-acting treatments to specific 
symptoms.   
It should be noted that a limitation of DA-acting pharmacotherapies, 
however, is that they are regionally non-specific. Given that our results suggest 
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that enhanced DA in the anterior insula may be associated with reduced 
motivation, a global DA agonist may have limited therapeutic effects, and may 
depend heavily on individual differences in regional responses. Further efforts to 
isolate specific DA projection pathways—either pharmacologically or via 
electrodes—may be required to best address motivational anhedonia.   
 
Limitations 
 While concerns regarding study-specific methodologies and designs have 
been discussed in the preceding chapters, there are nevertheless several 
general limitations that warrant additional comment. The first is the general lack 
of a simultaneous measure of affective responses to reward receipt during the 
EEfRT. While the current findings have been interpreted as evidence to suggest 
that motivational impairments may be present in MDD regardless of hedonic 
deficits, the studies included herein did not provide any clear evidence of this 
dissociation. It is therefore possible that MDD patients failed to work harder on 
the EEfRT simply because based on recent past experience (i.e., while 
depressed), they did not expect that the additional monetary rewards would lead 
to anything enjoyable. A recent study of effort-expenditure that used humorous 
cartoons as its primary rewards reported no difference in motivation between 
MDD patients and controls (Sherdell, et al., 2011). Importantly, Sherdell and 
colleagues collected affective ratings in response to the humorous cartoons, and 
found that both groups reported enjoying them to an equal degree. This may 
suggest that when presented with rewards that are valued similarly across 
91 
depressed and non-depressed groups, MDD patients are equally motivated to 
pursue them as controls. If true, such a result would suggest that decreased 
motivation is less impacted in MDD than would be suggested by the current 
findings. A related limitation is the reliance on monetary rewards as the only 
incentive used. Given that MDD in general and anhedonia in particular are often 
associated with diminished enjoyment of social rewards, as well as other forms of 
physical pleasure and sensation (e.g., reduced interest in sex), it could be argued 
that monetary rewards may not be fully representative of the breadth of 
rewarding experiences affected by anhedonia in MDD.  
 A second limitation is the complexity of the EEfRT task, which requires 
subjects to rapidly integrate information about effort expenditure, changing 
reward magnitudes and probability. As described in Chapter IV, the EEfRT was 
designed with several competing goals in mind, including translatability, relative 
ease of completion,  ecological validity (e.g., inclusion of the probability 
manipulation) and resistance to optimization strategies. A concern of these 
design elements however, is that MDD is commonly associated with 
psychomotor slowing and deficits in concentration. Consequently, the EEfRT 
may be more cognitively taxing for patient populations, which might explain some 
of the apparent sub-optimal decision-making patterns exhibited by patients.  
Finally, while the overarching goal of this work has been to identify 
pathophysiological mechanisms of motivational deficits within patient 
populations, the studies described herein did not include a measure of DA 
function in an MDD sample. Rather, inferences are drawn regarding the role of 
92 
DA in motivational deficits in MDD primarily from the identification of DAergic 
correlates of EEfRT performance in healthy subjects coupled with the 
observation of behavioral deficits on this measure in patients with MDD. While 
the results reported to date are promising, the lack of a direct comparison curtails 
the interpretability of these findings.  
   
Conclusions 
 Taken together, this work has sought to emphasize that anhedonia is a 
multifaceted construct, and that current clinical definitions and measures of 
anhedonia, which either fail to discriminate between motivational and 
consummatory aspects or ignore motivation altogether, are overly broad and 
underspecified for the purposes of pathophysiology. Much like the medical 
symptom of fever, anhedonia may have numerous manifestations and causes. 
To address this issue, we have recommended a general approach that seeks to 
reduce symptom-level heterogeneity by focusing on a particular, behavioral 
deficit (motivation) that both preclinical and clinical evidence suggests is linked to 
a specific pathophysiological mechanism (mesocorticolimbic DA). Through an 
integration of pharmacological, neuroimaging and clinical research methods with 
translational and “back-translational” approaches to assessment construction, the 
preliminary results of this program of research have been encouraging. Though 
clearly in its nascent stages, the findings reported above may eventually help 
personalize future treatments for anhedonia, and ultimately serve to reduce the 
overwhelming societal and individual costs of this debilitating symptom.  
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